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ABSTRACT 
Aims 
Degenerative eye diseases such as glaucoma are a leading cause of irreversible 
blindness, and traumatic optic neuropathies affect up to 5% of all patients with 
traumatic head injuries. Treatments are limited making cell based 
neuroprotective/neuroregenerative therapies a huge research interest. The aim of 
this PhD research project was to investigate the application of dental pulp stem cells 
(DPSC) as a treatment for traumatic and degenerative eye diseases. The accuracy 
and reliability of counting retinal ganglion cells (RGC) in radial retinal section was 
also assessed. 
Methods 
Numbers of RGC in radial retinal sections were compared to numbers in retinal 
wholemounts. To determine the feasibility of DPSC as a treatment for RGC loss they 
were cultured together and survival and neuritogenesis were quantified. DPSC were 
also transplanted intravitreally into rat models of optic neuropathy (optic nerve crush) 
and glaucoma and surviving RGC and regenerated axons were quantified in radial 
retinal sections. Finally, to determine the neurotrophic secretory profiles of 
mesenchymal stem cells and if this has a role in the mechanism of the 
neuroprotective and axogenic properties of DPSC, ELISA, PCR and inhibitory 
assays were performed. Adipose and bone marrow-derived mesenchymal stem cells 
(ADSC; BMSC) were used as comparative cells to the DPSC. 
Results 
Quantifying RGC in radial retinal sections was as reliable and accurate as the 
current gold standard Thus, retinal wholemounts with Brn3a proved to be the most 
reliable marker for RGC. DPSC proved to be more efficacious that BMSC/ADSC in 
protecting RGC from optic nerve crush-/glaucoma-induced death, promoting 
significant regeneration of RGC axons in the former and preserving visual function 
(as measured by electroretinography) in the latter. The mechanism of action, as 
determined in vitro, appeared to be through the secretion of multiple neurotrophic 
factors (NTF) including nerve growth factor, brain-derived neurotrophic factor, 
neurotrophin-3 and platelet-derived growth factor. 
Conclusions 
In conclusion, DPSC is a more potent cell therapy than BMSC/ADSC for the 
treatment of traumatic and degenerative disease, mostly acting through paracrine-
mediated mechanisms involving the secretion of multiple NTF, and preserve visual 
function in glaucomatous rats thus making them a potentially useful treatment for 
preventing blindness in glaucoma patients. 
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GENERAL INTRODUCTION 
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1.1 The visual system 
The visual system allows humans to perceive the world (visually) and is a vital aspect of 
independent functioning in the environment and in society. Loss of vision is a consequence 
of multiple traumatic and degenerative diseases and for many of these conditions, the 
resulting blindness is permanent. For example, 0.5-5% of traumatic head injuries result in 
optic neuropathies and blindness (Sarkies et al., 2004), and glaucoma is the leading cause 
of irreversible blindness, affecting 60 – 80 million worldwide (Quigley et al., 2006). No 
current treatments exist to alleviate the effects of optic neuropathy and treatment for 
glaucoma is symptomatic, restricted to the lowering of elevated intra-ocular pressure (IOP), 
even so 10% of treated patients still exhibit a permanent visual loss. 
1.2 The retina and optic nerve 
The retina is an outgrowth of the brain and is thus part of the central nervous system (CNS). 
Because of this, it is subject to the same limitations as other CNS tissue when damaged i.e. 
irreplaceable neurons and a lack of regenerative capacity. The retina (Figure 1) has three 
layers of neurons, an outer nuclear layer (ONL) composed of rod and cone photoreceptors, 
an inner nuclear layer composed of bi-polar cells/amacrine cells and a ganglion cell layer 
consisting of retinal ganglion cells (RGC). These layers make up the neural retina and sit 
upon the retinal pigment epithelium (RPE), adjacent to (but separated by Bruch’s 
membrane) the choroid. The RPE is necessary for ensuring regular turnover and recycling of 
photoreceptor outer segments whereas the vascular choroid provides nourishment to the 
eye. 
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Figure 1: Immunohistochemical staining of the retina (A) and optical coherence tomography 
(OCT) imaging of the retina (B). Retina is stained for a marker of retinal ganglion cells 
(Brn3a; green) and a nuclear marker (DAPI; blue). Labelled are the retinal nerve fibre layer 
(RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer 
plexiform layer (OPL), outer nuclear layer (ONL), photoreceptor cones and rods, and the 
choroid. Retinal pigment epithelium and Bruch’s membrane sit between the cones/rods and 
choroid (not shown). The differences in proportion are due to the significantly lower resolving 
power of OCT (B; scale bar: 200µm) in comparison to fluorescent microscopy (A; scale bar: 
50µm). 
Light, focussed on the retina by the lens, is detected by the cone and rod photoreceptors 
where it is converted into an electrochemical signal that travels through the bipolar cells to 
the RGC. Membrane depolarisations are propagated along the RGC axons in the retinal 
nerve fibre layer (RNFL) that exit the eye at the optic disc and course through the 
unmyelinated lamina cribrosa, then become myelinated by oligodendrocytes and make up 
the optic nerve. The axons of optic nerves of both eyes converge at the optic chiasm and 
decussate to project into contralateral optic tract before synapsing with relay neurons in the 
SC and LGN, from where signals are passed to the visual cortex, a feature necessary for 
stereoscopic vision (Berry et al., 2008). 
1.3 Degeneration and the axon regenerative capacity of retinal neurons 
The prevailing theory for the loss of RGC following traumatic or degenerative eye disease is 
the reduction in the vital supply of neurotrophic factors (NTF) which, under normal 
circumstances, are supplied from the innervated target and travel retrogradely along RGC 
axons to the RGC somata, acting as survival signals (Dawbarn and Allen, 2003). This is 
corroborated by a large body of literature on NTF-mediated neuroprotection of RGC (Barde, 
1989, Sofroniew et al., 2001, Jones et al., 2001, Morgan-Warren et al., 2013). During 
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development, neurons that fail to innervate their targets are starved of NTF survival signals 
and die by apoptosis (Butowt and von Bartheld, 2003). Similarly, many adult axotomised 
neurons atrophy and die after disconnection from target-derived NTF, but those with 
collaterals proximal to the transection site are protected by a supply of NTF derived from the 
targets of these collateral sites and also from local glia (Dougherty et al., 2000, Faulkner et 
al., 2004). Since axon collaterals are largely absent in the optic nerve, RGC are exquisitely 
sensitive to optic nerve damage, so that approximately 40% die within 7 days (Ahmed et al., 
2011) and 90% are lost by 14-21 days (Mey and Thanos, 1993, Berkelaar et al., 1994). The 
loss of axotomised RGC detailed above is of relevance to diseases such as glaucoma and 
traumatic optic neuropathy (TON) where axonal damage is sustained (Figure 2). 
5 
 
 
Figure 2: Schematic diagram of a parasagittal section of the eye and optic nerve 
demonstrating the neurodegenerative effects glaucoma and traumatic optic neuropathy and 
the potential for mesenchymal stem cells as a therapy (Adapted from Mead and Scheven. 
2015). 
The failure of adult CNS axotomised neurons to regenerate their axons is attributed to 
suppression of intrinsic axogenic machinery, the paucity of axogenic NTF (Berry et al., 2008) 
and the presence of myelin- and scar-derived axon growth inhibitory factors (Richardson et 
al., 1980, Sandvig et al., 2004) mediating growth cone collapse. This is in contrast to axons 
in the peripheral nervous system in which an abundance of Schwann cell-derived NTF 
contributes to the functional regeneration of their axons. The neurotrophins nerve growth 
factor (NGF), brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) 
phosphorylate tyrosine residues (Dawbarn and Allen, 2003) after binding to the tropomyosin 
related kinase (TrK) receptor and promote RGC survival and axon growth (Berry et al., 2008) 
by activating intracellular signalling pathways (MAPK/PI3K/PKC; Figure 3), whilst the 
cytokine ciliary neurotrophic factor (CNTF) activates the JAK pathway after binding to the 
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heterotrimeric gp130 receptor complex. These and other NTF signal through 
phosphoinositide-3-kinase (PI3K)/protein kinase B (Akt) to activate the serine-threonine 
kinase mammalian target of rapamycin (mTOR), to promote axogenic protein synthesis and 
inhibit glycogen synthase kinase-3β (GSK-3β) which, amongst other roles, regulates growth 
cone dynamics (Morgan-Warren et al., 2013). Experimental activation of mTOR signalling in 
adult mice promotes RGC survival and axon regeneration after optic nerve transection (Park 
et al., 2008, Morgan-Warren et al., 2013). Promoting axon regeneration is relevant to 
scenarios in which either the optic nerve is injured or RGC precursors are transplanted into 
the ganglion cell layer (Hertz et al., 2014) which subsequently require long distance 
regeneration of their axons. 
Along with loss of RGC, photoreceptor loss also occurs in many degenerative eye diseases 
such as age related macular degeneration (AMD) and retinitis pigmentosa. Photoreceptor 
outer segments are damaged by light and ultimately have a finite life, with 10% of the outer 
segments being recycled by RPE-mediated phagocytosis each day. RPE digestion of 
internalised phagosomes is not 100% efficient and toxic lysosomal proteins, such as 
lipofuscin, build up leading to RPE degeneration (Bharti et al., 2011). The thickening of the 
outer limiting membrane and successive reduction in the supply of diffusible factors to the 
RPE also contribute to the degeneration. The subsequent failure of the RPE to clear 
degenerate photoreceptor outer segments is the primary pathology in AMD and retinitis 
pigmentosa (Bharti et al., 2011). 
1.3.1 Current methods for quantifying neuronal damage and repair in the 
retina 
Animal models of traumatic and degenerative retinal eye disease are used to test potential 
neuroprotective and axogenic treatments. The optic nerve crush/transection (TON) and 
elevated IOP models of glaucoma, all experimentally induce chronic compression of the 
optic nerve. In TON, RGC axon regeneration can be measured in histological sections of the 
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optic nerve by staining for GAP-43. In contrast, the gold standard method of quantifying 
RGC loss and assessing the efficacy of neuroprotective treatments is to wholemount the 
retina and count the number of RGC in selected regions after staining the retina either with 
Brn3a or by back-labelling RGC with FluoroGold (Nadal-Nicolas et al., 2009). Unfortunately, 
the wholemounting technique is not always appropriate as it renders the tissue unusable for 
further analyses, meaning retinal sectioning is instead employed. The wide array of available 
models and analytical techniques now available has allowed researchers to test many 
different axogenic and neuroprotective treatments for ocular disease. 
1.4 Cellular therapy for CNS/retinal injury 
Treatments for long term neuroprotection and axon regeneration in damaged/diseased CNS 
tissue are limited and none are currently available in the clinic. Delivery of individual or 
combinations of NTF promotes incomplete and unsustained axon regeneration in the 
transected rat optic nerve (Logan et al., 2006) and spinal cord (Lu et al., 2004b). 
Accordingly, intravitreal (ivit) injection of recombinant BDNF and CNTF rescues axotomised 
RGC from death for up to 7 days (Mey and Thanos, 1993, Ahmed et al., 2011) but long term 
trophic support requires repeated low dose NTF injections (Ko et al., 2000, Ko et al., 2001) 
since transient high peak bolus delivery of NTF down-regulates TrK receptors (Sommerfeld 
et al., 2000, Chen and Weber, 2004). Injectable hydrogel formulations composed of 
collagen, alginate or chitosan are being developed (Pakulska et al., 2012) that continuously 
and slowly release low titres of NTF in vivo over several weeks. However, drug loading of 
implanted/injected hydrogels is limited and thus, for chronic neurodegenerative diseases like 
glaucoma, sustained NTF delivery requires repeated hydrogel implantation/injection, making 
FDA approval for clinical application a significant challenge. Alternative treatments, such as 
the transplantation of cells with extended longevity and engineered to continuously produce 
low levels of specific NTF combinations can remove the need for repeated injections and 
overcomes the problems of bolus NTF delivery regimes.  
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In contrast to this paracrine-mediated mechanism for neuronal rescue, cell therapy can be 
used to replace lost endogenous neurons and return, or prevent further loss of, function. For 
either of these two therapeutic approaches to achieve functional preservation, termed 
“indirect” and “direct” mechanisms, respectively, it has become apparent that stem cells are 
the most suitable candidates for this, as discussed below. 
1.4.1 Direct treatment mechanism – stem cell differentiation for cell 
replacement 
In AMD, replacement of RPE cells, either using the RPE cell line ARPE19 (Coffey et al., 
2002) or surgical translocation of the macula to a healthy portion of RPE (da Cruz et al., 
2007), preserves visual function, but a high rate of complications, such as retinal detachment 
and macular hole, means an alternative accessible source of exogenous RPE is preferred. 
Similarly, photoreceptor replacement by allogeneic subretinal transplantation of 
photoreceptor precursor cells isolated from retinae of gfp-expressing mice of various ages is 
effective (MacLaren et al., 2006). Experimentally transplanted photoreceptor precursors 
successfully survive, differentiate and integrate within the retina, improving retinal function 
and restoring vision, evident by the improvement in electroretinogram (ERG) performance 
and restoration of visual guided behaviour in animal models of photoreceptor loss (Pearson 
et al., 2012). However, the above approaches for photoreceptor/RPE cell replacement are 
not translatable as they utilize cell lines or primary cells from a deceased adult donor. 
Nevertheless, these proof-of-principle studies have led to research into the use of stem-
derived retinal cells for the replacement of cells lost in degenerative conditions. However, the 
propensity to which stem cells differentiate differ greatly between the different stem cell 
types. Equally, some retinal neurons, such as photoreceptors, are more easily derived than 
others like RGC, and thus RGC replacement is still in its infancy. 
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1.4.2 Indirect treatment mechanism – paracrine-mediated neuroprotection and 
axon regeneration 
Cells transfected with ntf genes or induced to secrete NTF have been grafted into the retina 
to treat retinal degeneration e.g. : (1), cells secreting BDNF, glial cell line-derived 
neurotrophic factor (GDNF) and NT-4 are RGC neuroprotective and improve visual function 
in cases of TON (Levkovitch-Verbin et al., 2010), sodium iodate-induced damage of the 
retina (Machalińska et al., 2013) and chronic ocular hypertension (Harper et al., 2011); (2), 
ivit transplantation of genetically engineered fibroblasts that over express fibroblast growth 
factor-2 (FGF-2), NT-3 and BDNF significantly increase RGC survival and axon regeneration 
after optic nerve crush (Logan et al., 2006); (3), cells engineered to secrete CNTF attenuate 
photoreceptor death in mouse models of retinitis pigmentosa (Jung et al., 2013); (4), neural 
progenitor cells transfected with crystallin-β-b2 promote both RGC and photoreceptor 
survival (Bohm et al., 2012); and (5), a glucagon-like peptide-1-secreting cell line promotes 
RGC survival after optic nerve crush (Zhang et al., 2011). Despite possible adverse effects, 
cell transplantation “mono-therapies” offer the potential advantages of continuous secretion 
of multiple NTF for the duration of the viability of the transplant, which bind to multiple 
receptors and thus signal survival and axon regeneration through multiple signalling 
pathways (Figure 3). Interestingly, many types of stem cells, in particular mesenchymal stem 
cells (MSC), innately secrete a wide array of NTF, making them a suitable paracrine-
mediated cellular therapy (Figure 2). 
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Figure 3: A schematic diagram showing the proposed mechanism by which MSC exert their 
neurotrophic effects on the injured CNS, including the retina, through secretion of NGF, 
BDNF, NT-3, CNTF GDNF, VEGF, FGF and PDGF which engage TrK A, B and C, CNTFα, 
GFRα, VEGFR, FGFR1 and PDGFR receptors, respectively, leading to the activation of 
intracellular pathways for axon growth, axon growth disinhibition and neuroprotection, 
accounting for the functional recovery seen in animals receiving MSC transplants after 
CNS/retinal injury. Some ligand-receptor interactions activate the same signalling pathways. 
(Abbreviations: BAD, bcl-2-assosciated death promoter; Bcl2, B-cell lymphoma 2; FGFR1, 
fibroblasts growth factor receptor 1; FRS2, fibroblast growth factor receptor substrate 2; 
GFRα, GDNF family receptor alpha; Grb2, growth factor receptor-bound protein 2; IAPS, 
inhibitor of apoptosis; MAPK, mitogen-activated protein kinase; Mek, mitogen-activated 
protein kinase kinase; PDK, phosphoinositide-dependant kinase; PKC, protein kinase C; 
PLCγ, phospholipase C-gamma). (Taken from Mead et al., 2015). 
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1.5 Characterization of different types of stem cells 
Stem cells are defined as self-renewing cells with the capacity to differentiate into multiple 
cell types. Stem cells fall into the following categories: (1), totipotent stem cells can 
differentiate into both embryonic and extra-embryonic cells; whereas (2), pluripotent stem 
cells can only form cells from the three embryonic germinal layers, ectoderm, mesoderm and 
endoderm; (3), multipotent stem cells that are more restricted than pluripotent stem cells in 
their differentiation potential; finally (4), progenitors (which are not strictly stem cells) have 
already undergone commitment so that further differentiation is restricted to cells of a 
particular tissue, e.g. retinal progenitors can generate replacement cells in both the neural 
retina and RPE. 
1.5.1 Embryonic stem cells/induced-pluripotent stem cells 
Embryonic stem cells (ESC) are Tra-1-60+/Tra-1-81+/SSEA-3+/SSEA-4+/Oct4+/Nanog+/Sox2+ 
self-renewing pluripotent stem cells isolated from the inner cell mass of the blastocyst 
(Thomson et al., 1998) that can form cells from all three embryonic germinal layers, including 
mature neurons (Reubinoff et al., 2000). Induced pluripotent stem cells (iPSC) are ESC-like 
cells generated from somatic cell reprogramming by forcing the expression of the four 
transcription factors: Oct4, Sox2, Myc and Klf4 (Takahashi and Yamanaka, 2006). Although 
iPSC are characteristically similar to ESC, subtle differences in genetics/epigenetics have 
been observed (Doi et al., 2009, Kim et al., 2010). 
1.5.2 Neural stem cells 
Isolated from the CNS of adult and aborted foetus cadavers (Lu et al., 2012, McGill et al., 
2012), neural stem cells (NSC) are self-renewing and multipotent with the potential to 
differentiate into neurons, astrocytes and oligodendrocytes, both in culture and in vivo 
(Clarke et al., 2000). NSC do not express unique markers and are identified by their 
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characteristics of neurosphere formation, differentiation potential and nestin expression 
(Bazan et al., 2004), a phenotypic marker for neuronal precursor cells (Lendahl et al., 1990). 
1.5.3 Bone marrow-derived MSC 
Originally described as fibroblast colony forming units (Friedenstein et al., 1966, Friedenstein 
et al., 1970), bone marrow-derived mesenchymal stem cells (BMSC; also referred to as 
bone marrow stromal cells) are CD29+/CD44+/CD73+/CD90+/CD45- (Minguell et al., 2001, 
Karaoz et al., 2011) self-renewing multipotent cells isolated from bone marrow aspirates. 
Although their precise biological function is uncertain, they can differentiate along 
chondrogenic, adipogenic and osteogenic lineages (Pittenger et al., 1999). Despite early 
reports of differentiation into non-mesodermal lineages such as neurons (Woodbury et al., 
2000), later evidence disputes the neural differentiation capacity of MSC and conclusive 
evidence for the differentiation of BMSC into functional neurons is lacking (Lu et al., 2004a). 
1.5.4 Adipose-derived MSC 
Adipose-derived mesenchymal stem cell (ADSC) frequencies are higher in lipoaspirates 
from cosmetic liposuction surgery and abdominoplasty (Kern et al., 2006, Kalbermatten et 
al., 2011) than those of BMSC in bone marrow aspirates (Kingham et al., 2007) and thus are 
arguably the most readily available stem cells for use in regenerative medicine. Like BMSC, 
ADSC are multipotent CD29+/CD44+/CD73+/CD90+/CD45- (Kern et al., 2006, Zhou et al., 
2013) with some evidence for the differentiation into neurons and glia (Kang et al., 2003), but 
evidence for these ADSC-derived neurons being functional is lacking. 
1.5.5 Dental pulp stem cells 
Neural crest-derived dental pulp stem cells (DPSC) (Chai et al., 2000) are 
nestin+/CD29+/CD44+/CD73+/CD90+/CD45- (Kiraly et al., 2009, Kawashima, 2012, Sakai et 
al., 2012) cells with self-renewal and multipotent differentiation properties (Gronthos et al., 
2002) and the potential to differentiate into neurons (Arthur et al., 2008, Kiraly et al., 2009). 
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They are readily isolated from the pulp of the 3rd/4th adult molars (Gronthos et al., 2000, 
Arthur et al., 2008) and can be expanded and stored for future use. Dental stem cells can 
also be isolated from the deciduous teeth of infants (Huang et al., 2009), which include 
exfoliated deciduous teeth (SHED) (Miura et al., 2003) and those from the apical papilla of 
immature teeth (SCAP) (Sonoyama et al., 2008). Cells from all origins have rapid 
proliferation rates and can differentiate along chondrogenic, adipogenic and osteogenic 
lineages (Sonoyama et al., 2008, Wang et al., 2012). 
1.6 Fate of intraocular transplanted stem cells 
The potential of stem cells to treat eye disease is dependent on their fate following ivit and 
sub-retinal transplantation and thus the incidence of immune rejection, differentiation into 
unpredicted phenotypes and unbridled migration within the neuropil of the retina, together 
with possible oncogenesis. Safeguards against these adverse outcomes include 
encapsulation of the stem implant (Zhang et al., 2011) and the employement of inducible 
suicide genes, such as viral-derived thymidine kinase, allowing selective destruction of the 
transplanted cells when organisms are treated with the toxic drug ganciclovir (Zhang et al., 
2011). However, the potential risks of transplanting stem cells in the eye may have been 
exaggerated because intraocular cell movement is restrained and immune reactions muted. 
1.6.1 Survival and migration of intraocular transplanted stem cells 
In the eye, MSC survive for at least 3 - 5 weeks (Johnson et al., 2010, Levkovitch-Verbin et 
al., 2010, Haddad-Mashadrizeh et al., 2013), cluster in the vitreous body (Johnson et al., 
2010, Haddad-Mashadrizeh et al., 2013) with a small number migrating into the retina with 
no observation of either tumorigenesis or uncontrolled proliferation (Johnson et al., 2010, 
Singh et al., 2012, Mendel et al., 2013, Mesentier-Louro et al., 2014, Tzameret et al., 2014, 
Tan et al., 2015). After subretinal transplantation, NSC remain immature for at least 7 
months, barely proliferate and neither exhibit uncontrolled growth nor oncogenesis, but they 
do migrate from the injection site within the subretinal space (McGill et al., 2012, Lu et al., 
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2013). By contrast, after ivit transplantation, NSC either attach to the retina and lens, where 
they remain (Jung et al., 2013), or integrate into the inner retinal layers (Grozdanic et al., 
2006). ESC-derived RPE cells transplanted into the subretinal space of Royal College of 
Surgeon (RCS) rats (which spontaneously undergo RPE and subsequent photoreceptor 
degeneration) survive for over 200 days, preserve visual function with no evidence of either 
teratoma formation (Lu et al., 2009) nor proliferation (Vugler et al., 2008). Reactive retinal 
astrogliosis rather than penetration of the internal limiting membrane is proposed as a major 
limitation to retinal integration of ESC after ivit implantation (Banin et al., 2006); while, after 
subretinal grafting, cell migration is more extensive (Banin et al., 2006, Lamba et al., 2009) it 
is still hindered by the outer limiting membrane (West et al., 2008). 
1.6.2 Immunological acceptance of intraocular transplanted stem cells 
The vitreous cavity, like the anterior chamber of the eye, is an immunoprivileged 
environment (Jiang and Streilein, 1991) and thus amenable to cell transplantation. MSC fail 
to trigger an immune response when challenged with allogeneic lymphocytes and MSC-
derived factors inhibit the proliferation of immunological cells (Kode et al., 2009, Singer and 
Caplan, 2011). These immunosuppressive/immunomodulatory actions of BMSC have led to 
Phase I (Le Blanc et al., 2004), Phase II (Le Blanc et al., 2008) and Phase III (Martin et al., 
2010) clinical trials for the treatment of steroid refractory graft-versus-host disease. ADSC 
suppress the immune system with the same efficacy as BMSC in vitro (Puissant et al., 2005) 
and increase the survival rate of transplants in animal models of graft versus host disease 
(Yañez et al., 2006), whereas DPSC are as efficient as BMSC in the suppression of T cell 
proliferation in vitro (Pierdomenico et al., 2005). Thus, the failure of the host to launch 
immune reactions after ivit/subretinal implantation of MSC is probably explained by both the 
immune privileged status of these sites and the immunosuppressive properties of MSC. For 
example, immunosuppression is not required and adverse effects are not recorded after 
intravitreal transplantation of human BMSC (Johnson et al., 2010, Levkovitch-Verbin et al., 
2010, Tzameret et al., 2014) and ADSC (Haddad-Mashadrizeh et al., 2013). Equally, 
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although not immunosuppressive, iPSC-derived from the somatic cells of the recipient would 
carry the same histocompatibility antigens as the host and do not require 
immunosuppression after transplantation. By contrast, ESC/NSC require 
immunosuppression when transplanted into the CNS since autologous transplantation is not 
possible (Cummings et al., 2005, Lu et al., 2012, Schwartz et al., 2012, Lu et al., 2013). For 
example, NSC transplantation into the subretinal space requires daily immunosuppressive 
treatment with cyclosporine A and dexamethasone (McGill et al., 2012). When transplanted 
into the vitreous without immunosuppression, NSC are detected in just 50% of transplanted 
eyes 32 days after grafting (Grozdanic et al., 2006), suggesting that the immunoprivileged 
environment of the vitreous does not sustain survival of NSC. ESC-derived RPE cells were 
one of the first ESC based therapies to be used in humans and early reports of subretinal 
transplantation as a treatment for AMD confirm their safety, although patients require 
immunosuppression throughout (Schwartz et al., 2012). 
1.7 Potential of stem cells as a cellular therapy for traumatic and degenerative 
eye disease 
A wealth of evidence exists on the use of stem cell for treating a wide array of traumatic and 
degenerative eye conditions which has led to a multitude of clinical trials. 
1.7.1 Embryonic stem cells/induced-pluripotent stem cells 
The greatest potential for cell replacement has been realised with ESC/iPSC, which are 
predifferentiated prior to transplantation into the eye, with the most success demonstrated in 
RPE/photoreceptor replacement for AMD. 
 ESC can be directed towards a retinal phenotype with developmental induction signals 
including bone morphogenetic protein (BMP) antagonists (Lamb et al., 1993), Wnt inhibition 
(Wilson and Houart, 2004) and insulin-like growth factor (IGF) treatment (Pera et al., 2001). 
Accordingly, 30% of ESC/iPSC differentiate into retinal progenitors (Ikeda et al., 2005), 
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increasing to 80% for both ESC (Lamba et al., 2006) and iPSC (Tucker et al., 2011) by 
incorporating BMP/Wnt inhibiton with IGF and FGF treatments. These ESC/iPSC-derived 
retinal progenitors successfully mature into photoreceptors as well as RPE cells and 
integrate into retinal explants after either co-culture with adult retina/retinal neurons 
(Osakada et al., 2008) or after the addition of a cocktail of small molecules (Osakada et al., 
2009b). Comparisons of the gene expression profiles of ESC-derived retinal cells with 
primary developing foetal retinal cells using microarray analysis shows them to be highly 
conserved between the two cell sources throughout development (Lamba and Reh, 2011).  
ESC-derived retinal progenitors, primed with FGF to form retinal neurons rather than RPE 
cells, successfully differentiate into photoreceptors (Hambright et al., 2012), integrate into 
the ONL (Lamba et al., 2009) and survive for over 3 months in the subretinal space of non-
immunosuppressed mice with an intact blood-retinal barrier, with integration into the retina 
more significant when it is injured (Hambright et al., 2012). iPSC-derived photoreceptors 
transplanted into the subretinal space integrate into the ONL and increase retinal function as 
determined by ERG (Tucker et al., 2011). Ivit transplanted ESC topographically integrate into 
all the layers of the mouse retina, i.e. ESC-derived photoreceptors move to the ONL, and 
ESC-derived amacrine cells and RGC-like cells migrate to the inner nuclear layer/ganglion 
cell layer, respectively (Lamba et al., 2009, Reynolds and Lamba, 2013). However, 
integration is only possible up to 48 hours after birth, corroborating reports that in adult rats, 
ivit ESC-derived cells fail to integrate into the retina (Banin et al., 2006). 
Both mouse (Eiraku et al., 2011) and human (Nakano et al., 2012) ESC can be induced to 
form a complete topographically organized retina, including the RPE. Developing 
photoreceptors, isolated from ESC-derived ex vivo retina, integrate after transplantation into 
mouse models of retinal degeneration (Gonzalez-Cordero et al., 2013). These findings have 
been replicated using iPSC showing the formation of a synaptically connected stratified 
retina (Phillips et al., 2012). 
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ESC/iPSC can be induced to differentiate into RPE cells using similar protocols to those 
described above, but with the omission/antagonism of FGF to bias the generation of RPE 
cells over neural retina (Meyer et al., 2009, Osakada et al., 2009a). These ESC/iPSC-
derived RPE cells phagocytise photoreceptor outer segments (Carr et al., 2009a) and 
preserve retinal function in the RCS rats (Vugler et al., 2008, Carr et al., 2009b). A study 
comparing adult human ESC-derived RPE with foetal human RPE demonstrated a strong 
correlation in their gene expression profiles. However, iPSC-derived RPE have a distinct 
gene expression profile, indicating potential differences between ESC- and iPSC-derived 
retinal cells (Liao et al., 2010). 
Subretinal transplantation of ESC/iPSC-derived RPE in cases of AMD require approximately 
60,000 cells (Bharti et al., 2011) to restore RPE-mediated recycling of photoreceptor outer 
segments. In contrast to photoreceptor replacement, in this instance significant migration, 
integration and synaptogenesis is not required to achieve functional efficacy. The 
effectiveness of RPE replacement is already proven by the fact that current surgical 
intervention relies on the same principles i.e. translocating the macula to an adjacent, 
healthy portion of RPE (da Cruz et al., 2007). These attributes have led to the first clinical 
trial transplanting ESC-derived RPE cells in patients with AMD (Schwartz et al., 2012) 
(Figure 4). 
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Figure 4: A diagram showing the proposed way in which ESC/iPSC-derived RPE and 
photoreceptors can be used to treat AMD/photoreceptor degeneration. The left panel shows 
a rat retina immunohistochemically stained for cone annexin (cone photoreceptor marker; 
green), Brn3a (RGC marker; red) and DAPI (nuclear marker; blue) with individual layers 
labelled (scale bar: 100µm). On the right, RPE is represented together with photoreceptor 
loss in AMD and the potential for cell replacement in preventing visual decline and restoring 
vision. 
 
ESC/iPSC differentiate into RGC and, during the formation of ESC-/iPSC-derived retina ex 
vivo, RGC are the first cells to develop which mimics normal retinal development (Eiraku et 
al., 2011, Nakano et al., 2012, Phillips et al., 2012). The yield of RGC is enhanced by 
transfection of the stem cells with genes regulating RGC development, namely math5 and 
sox4 (Jiang et al., 2013). Similar to ESC/iPSC-derived photoreceptors integrating into the 
ONL, transplanted adult rat RGC integrate and survive in the ganglion cell layer (Hertz et al., 
2014) but, unlike photoreceptors, the long distances over which RGC axons must regenerate 
to re-innervate central targets is unachievable (Sun et al., 2011). 
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Unlike MSC, the paracrine potential of ESC/iPSC for treating the injured retina/CNS is as yet 
unknown. Addition of TrK receptor blockers to ESC cultures perturbs their survival, indicating 
that neurotrophins are released and active in an autocrine fashion, but further analysis on 
the secretome is required (Pyle et al., 2006). Ivit transplantation of ESC-derived 
photoreceptors promotes the survival of nearby endogenous photoreceptors (Meyer et al., 
2006). Similarly it is known that RPE cells secrete vascular endothelial growth factor (VEGF) 
and pigment epithelium-derived factor, which may further explain how ESC-derived RPE 
protect photoreceptors from death (Strauss, 2005).  
1.7.2 Neural stem cells 
NSC transplantation is beneficial to recovery in a range of CNS injury models, including 
retinal degeneration (McGill et al., 2012), spinal cord injury (SCI) (Lu et al., 2003, Abematsu 
et al., 2010, Lu et al., 2012), stroke (Jeong et al., 2003) and traumatic brain injury (TBI) 
(Riess et al., 2002), although in many cases it is unclear if the improved functional recovery 
observed is attributable to replacement of lost cells and/or trophic support of surviving cells. 
For example, when transplanted into injured CNS sites, such as those of SCI and TBI, NSC 
differentiate into neurons and glia (Riess et al., 2002, Jeong et al., 2003, Cummings et al., 
2005, Martino and Pluchino, 2006, Abematsu et al., 2010, Lu et al., 2012), replacing lost 
cells and providing trophic support for damaged endogenous neurons (Lu et al., 2003). NSC 
differentiation is greatly enhanced by containment in a matrix loaded with multiple growth 
factors (Lu et al., 2012) and treatment with specific differentiation factors (Cao et al., 2001). 
In these instances, functional recovery is attributed to the generation of new NSC-derived 
neurons that directly integrate into the host neuronal circuitry (Martino and Pluchino, 2006, 
Abematsu et al., 2010) and not to the paracrine mediated axon regeneration and 
neuroprotection characteristic of MSC treatment.  
Despite recent successes with NSC in other CNS injury models, few studies have shown the 
same effects in the eye. In rats, ivit transplantation of NSC after optic neuropathy induced by 
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elevated IOP, does not improve retinal function despite neuronal differentiation and 
integration into inner retinal layers (Grozdanic et al., 2006). A similar study using mice 
lacking RGC (apoptosis induced by removal of the superior colliculus) showed that NSC 
integrate into the retina but sparsely form βIII-tubulin+ mature neurons and do not form 
functional RGC (Mellough et al., 2004). Re-innervation of central targets by the axons of 
RGC replaced by stem cells is currently not possible. Indeed, more success has been seen 
in RCS rats in which the retinal degeneration is of the photoreceptors rather than the RGC 
(McGill et al., 2012). Subretinal transplantation of NSC protects photoreceptors from death in 
RCS rats (McGill et al., 2012) by phagocytosis of photoreceptor outer segments, a role 
usually restricted to RPE cells which, in RCS rats, are dysfunctional (Cuenca et al., 2013). 
Although a paracrine effect (i.e. secretion of NTF) has been suggested to mediate the effects 
of NSC in the retina, studies have only demonstrated this mechanism when NSC are 
genetically modified (e.g. to secrete CNTF (Jung et al., 2013)). The limited number of studies 
suggests that NSC are not currently viewed as useful for replacement of RGC. However, 
functional replacement of photoreceptors by NSC is more plausible because of their short 
synaptic distances. Despite this, integration of NSC into the ONL is not followed by 
differentiation into calbindin+/rhodopsin+ mature photoreceptors (Nishida et al., 2000) and 
subretinal transplanted NSC protect, rather than replace photoreceptors (McGill et al., 2012, 
Jung et al., 2013). 
Following transplantation into SCI lesion sites, NSC increase the expression of NGF, BDNF, 
NT-3 and GDNF within the lesion site (Gu et al., 2012, He et al., 2012) and promote axonal 
sprouting (Lu et al., 2003). However, the trophic support provided by undifferentiated NSC 
only minimally restores function when compared to strategies when they are induced to 
differentiate down a neuronal lineage before or after transplantation into SCI sites (Cao et 
al., 2001, Abematsu et al., 2010, Gu et al., 2012, He et al., 2012). In the eye, as stated 
above, ivit NSC transplanted into the vitreous fail to improve function in models of elevated 
IOP-induced RGC loss (Grozdanic et al., 2006) and axotomy (Flachsbarth et al., 2014), and 
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are neuroprotective only when transfected to secrete CNTF. However, in this study 
transplantation was made four weeks post-injury, so that it cannot be ruled out that NSC 
may be able to have a paracrine-mediated neuroprotective effect on RGC when transplanted 
at the time of RGC injury. Nonetheless, after subretinal transplantation of NSC in RCS rats, 
rather than being replaced, photoreceptors are protected against death by NSC-directed 
phagocytosis of photoreceptor outer segments (Cuenca et al., 2013) and induction of CNTF 
expression by Müller glia (Lu et al., 2013). 
1.7.3 Bone marrow-derived MSC 
Apparent in vitro neuronal differentiation and neuritogenesis of BMSC is probably 
artefactual, resulting from cell shrinkage and toxicity yielding cell morphologies characteristic 
of neurons (Lu et al., 2004a, Neuhuber et al., 2004). Undifferentiated BMSC co-express 
many functional ion channels (Li et al., 2006) as well as mature neuronal and glial markers, 
such as βIII-tubulin and glial fibrilliary acidic protein (GFAP), respectively (Karaoz et al., 
2011, Tamaki et al., 2012) making successful phenotypic differentiation difficult to detect. 
The ability of BMSC to differentiate into neurons and replace those lost from injury is rarely 
reported in vivo (Vallières and Sawchenko, 2003). Their transplantation into the injury site 
after SCI promotes functional recovery without any evidence of neuronal replacement by 
BMSC differentiation (Kang et al., 2012). 
In the eye, transplantation of BMSC into the vitreous after experimentally-induced glaucoma 
and optic nerve transection demonstrate no evidence of stem cell differentiation into mature 
retinal cells, despite some integration into the retina (Yu et al., 2006, Johnson et al., 2010, 
Levkovitch-Verbin et al., 2010, Mesentier-Louro et al., 2014). After transplantation into the 
subretinal space in RCS rats and mouse models of retinitis pigmentosa, some BMSC 
differentiate into cells with neuronal and glial characteristics, but not into mature 
photoreceptors or RPE cells (Zhang and Wang, 2010, Tzameret et al., 2014) and a 
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protective effect on endogenous photoreceptors and RPE cells is observed (Arnhold et al., 
2007, Lu et al., 2010).  
The neurotrophic secretome of BMSC, which includes NGF, BDNF, NT-3, NT-4/5, CNTF, 
GDNF and platelet-derived growth factor (PDGF) is widely documented (Dormady et al., 
2001, Chen et al., 2005, Wilkins et al., 2009, Ghorbanian et al., 2012, Sakai et al., 2012, 
Johnson et al., 2014) and places them as a candidate cellular therapy to combat ocular 
neurodegeneration. BMSC-mediated neuroprotection of RGC is reported to be mediated by 
PDGF (Johnson et al., 2014). The importance of BMSC-derived NTF for retinal neuron 
survival is confirmed by using TrK and PDGFR inhibitors which significantly diminish the 
RGC neuroprotection and/or neurite growth effects elicited by BMSC (Johnson et al., 2014). 
The vitreous does not permit the differentiation of BMSC into neurons (Hill et al., 2009). 
Nonetheless, ivit transplanted BMSC secrete diffusible factors directly protecting RGC from 
death in animal models of glaucoma (Yu et al., 2006, Johnson et al., 2010, Emre et al., 
2015) and optic nerve transection (Levkovitch-Verbin et al., 2010, Mesentier-Louro et al., 
2014, Tan et al., 2015), and these cells can also be indirectly effective by inducing Müller cell 
NTF production (Lee et al., 2012). Interestingly, BMSC also promote the regeneration of 
RGC axons after optic nerve crush (Mesentier-Louro et al., 2014, Tan et al., 2015), probably 
through the same NTF-mediated mechanisms (Berry et al., 2008). Subretinal and ivit BMSC 
transplantation in RCS rats and mouse models of retinitis pigmentosa significantly improves 
retinal function by preserving photoreceptor and RPE cell viability (Arnhold et al., 2007, Lu et 
al., 2010, Tzameret et al., 2014) and, although the underlying observations remain 
equivocal, a role for the NTF secretome in promoting cell survival is a likely explanation. 
1.7.4 Adipose-derived MSC 
There is conflicting evidence for the differentiation of ADSC into neurons in vivo and in vitro 
(Anghileri et al., 2008, Ye et al., 2010). BDNF/retinoic acid treatments induce the 
differentiation of ADSC into functional neurons, confirmed by patch clamp analysis and the 
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expression of phenotypic neuronal markers (Anghileri et al., 2008). The differentiation of 
ADSC into neuronal phenotypes, demonstrated in this and other studies (Ye et al., 2010) is 
only transient with de-differentiation occurring after withdrawal of the differentiation-inducing 
medium (Ye et al., 2010), explaining why ADSC-derived neurons are rarely seen in vivo after 
transplantation in animal models of stroke (Kang et al., 2003). Both studies (Kang et al., 
2003, Ye et al., 2010) concluded that cerebrospinal fluid and the CNS neuropil do not 
sustain neuronal differentiation of ADSC. By contrast, ADSC pre-differentiated into 
NG2+/S100+ glia survive for up to 8 weeks after transplantation into rodent SCI sites 
(Arboleda et al., 2011) and thus, like other MSC, probably differentiate preferentially into glia 
in vivo (Cao et al., 2001, Cho et al., 2009, Leong et al., 2012). 
ADSC survive for up to 90 days in the vitreous after transplantation, although their fate has 
not been studied (Haddad-Mashadrizeh et al., 2013). Interestingly, ADSC transplanted into 
the vitreous of mouse models of diabetic retinopathy preferentially differentiate into 
pericytes, associating with and conserving the retinal vasculature, suggesting a potentially 
unique role for ADSC in treating diabetic retinopathy (Mendel et al., 2013). The failure of 
ADSC to integrate into the retinal layers diminishes their potential for RGC and 
photoreceptor replacement (Mendel et al., 2013). 
ADSC express NGF, BDNF, NT-3, GDNF, VEGF and PDGF (Kalbermatten et al., 2011, 
Zhou et al., 2013), with titres of BDNF and VEGF being significantly higher than those 
secreted by BMSC (Zhou et al., 2013). Despite this, ADSC are relatively untested in the eye 
but have efficacy as a paracrine-mediated therapy in other CNS injury animal models like 
SCI (Arboleda et al., 2011, Zhou et al., 2013) and stroke (Kang et al., 2003). A recent study 
demonstrated a neuroprotective effect of ivit transplanted ADSC in an experimental model of 
closed angle glaucoma with similar efficacy to that of BMSC (Emre et al., 2015). In co-
culture, ADSC-derived NTF promote neuroprotection and neuritogenesis of injured RGC. In 
a mouse model of light induced photoreceptor damage, both ivit ADSC and ADSC-
conditioned medium preserve ONL thickness and the amplitude of the a-wave of the ERG 
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(Sugitani et al., 2013, Tsuruma et al., 2014). Progranulin, tissue inhibitor of 
metalloproteinases-1 (TIMP1) and the secreted protein rich in cysteine (SPARC) are the 
active agents produced by ADSC in vitro and, after ivit transplantation, have similar effects to 
ivit ADSC/ADSC conditioned medium. Together, these data suggest that ADSC have 
therapeutic potential for neurodegenerative conditions through NTF production, with many of 
the active factors different from those produced by BMSC and DPSC. 
1.7.5 Dental pulp stem cells 
DPSC have been reported to differentiate into functionally active neurons in vitro (Arthur et 
al., 2008, Kiraly et al., 2009, Gervois et al., 2014). Following transplantation, DPSC integrate 
and survive in injured rat brain tissue for at least 4 weeks (Kiraly et al., 2011, Fang et al., 
2013). Other studies demonstrate that, although DPSC-derived neurons express neuronal 
phenotypic markers, they neither generate action potentials nor form functional neuronal 
networks (Aanismaa et al., 2012). Like BMSC, they constitutively express mature neuronal 
and glial phenotypic markers even in an undifferentiated state and this may explain the 
contradictions in the literature, if these characteristics are taken as a read out of successful 
differentiation (Karaoz et al., 2011, Tamaki et al., 2012). In vivo, transplantation of DPSC into 
rat SCI lesion sites leads to functional recovery yet only glial, not neuronal differentiation is 
observed (Sakai et al., 2012), suggesting that differentiation of DPSC into neurons is 
possible in vitro but currently has not yet been realised in vivo. 
Like other MSC, DPSC express (gene expression, as measured by PCR) multiple NTF 
including ngf, bdnf, nt-3, gdnf, vegf and pdgf (Nosrat et al., 1997, Nosrat et al., 2001, Gale et 
al., 2011, Sakai et al., 2012). Interestingly, DPSC express significantly greater amounts of 
ngf, bdnf and nt-3 mRNA than BMSC (Sakai et al., 2012). DPSC-conditioned medium 
containing the above factors promotes neurite outgrowth of both cortical neurons (Sakai et 
al., 2012) and a neuroblastoma cell line (Ishizaka et al., 2013) with significantly greater 
efficacy than BMSC-conditioned medium. DPSC transplanted into mouse hippocampus 
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increase the basal expression levels of many NTF such as CNTF, VEGF, FGF-2 and NGF 
(Huang et al., 2008), although it is unknown if the transplanted DPSC directly expressed 
these NTF and/or indirectly promoted the expression of NTF by neighbouring cells in the 
surrounding neuropil.  
DPSC transplantation into rat SCI lesion sites leads to greater functional improvement than 
after BMSC transplantation and, with a lack of observable neuronal differentiation, the data 
strongly suggests a paracrine-mediated mechanism (Sakai et al., 2012). Currently, no 
evidence exists for DPSC-mediated protection of retinal cells and/or regeneration of their 
axons. However, current evidence from other areas of the CNS strongly suggests that DPSC 
may be an applicable cellular therapy that warrants further research. 
1.8 Aims and hypotheses 
1.8.1 Aims 
This project aimed to assess the efficacy of DPSC as a paracrine-mediated therapy for 
traumatic (TON) and degenerative (glaucoma) eye disease, in comparison to BMSC and 
ADSC, two more widely researched MSC. Firstly, the accuracy and reliability of counting 
RGC in radial sections of retina was assessed and compared to the current gold standard 
method of retinal wholemounts. This was necessary as retinal wholemounts are not ideal for 
assessing RGC numbers in stem cell transplanted animals as it renders the tissue unusable 
for further analyses, such as assessment of grafted stem cell survival and migration. The 
second aim was to compare the axogenic and neuroprotective properties of DPSC and 
BMSC after transplantation into the vitreous of an animal model of TON. The third aim was 
to determine the mechanism by which MSC including DPSC, BMSC and ADSC induced the 
survival of RGC and regeneration of their axons by co-culturing them with injured RGC with 
NTF receptor blockers. The final aim was to compare the potential benefits of DPSC, BMSC 
and ADSC as paracrine-mediated cellular therapies for glaucoma, assessing their ability not 
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only to protect RGC from death but also preserve the function of the retina and ultimately, 
vision. 
1.8.2 Hypotheses 
The first hypothesis (1) proposes that the technique used to quantify RGC numbers in radial 
sections of retina, is a reliable and accurate measure of RGC survival. The second 
hypothesis (2) proposes that, following transplantation into the vitreous of animals after an 
optic nerve crush, both BMSC and DPSC will promote survival of RGC and regeneration of 
their axons, with DPSC as the most efficacious. Further (3), the mechanism behind the 
neuroprotective and axogenic properties of DPSC/BMSC relates to a wide array MSC-
derived NTF which activate their cognate receptors on RGC and promote survival and 
regeneration of their axons. Finally (4), it is hypothesised that, when transplanted into the 
vitreous of animals after induction of glaucoma, DPSC and, to a lesser extent BMSC and 
ADSC promote the protection of RGC and preserve retinal function. 
1.9 Experimental approach 
To test these hypotheses, (1) optic nerves were crushed and RGC death determined by 
quantification of Brn3a+ RGC in radial retinal sections/wholemounts and retrogradle 
FluoroGold back-labelled RGC in wholemounts. Hypothesis 2 was tested by transplanting 
either DPSC or BMSC (dead or alive) into the vitreous of animals after optic nerve crush. 
Survival and regeneration were assessed using immunohistochemistry and OCT. 
Hypothesis 3 was tested by culturing the stem cells with primary injured RGC, separated 
from each other by a permeable membrane to allow only diffusible factors to be the means 
of interaction. Alongside this, highly specialised inhibitors of select NTF receptors were used 
to discover the relative importance of each secretable NTF. Hypothesis 4 was tested using a 
TGF-β mediated model of glaucoma in which DPSC, BMSC or ADSC were intravitreally 
transplanted. After 5 weeks, the retinae were analysed using ERG (function), OCT 
(morphology) and immunohistochemistry (RGC quantification). 
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Abstract 
To investigate the reliability of different methods of quantifying retinal ganglion cells (RGCs) 
in rat retinal sections and wholemounts from eyes with either intact optic nerves or those 
axotomised after optic nerve crush (ONC). Adult rats received a unilateral ONC and after 21 
days the numbers of Brn3a+, βIII-tubulin+ and Islet-1+ RGCs were quantified in either retinal 
radial sections or wholemounts in which FluoroGold (FG) was injected 48h before 
harvesting. Phenotypic antibody markers were used to distinguish RGCs from astrocytes, 
macrophages/microglia and amacrine cells. In wholemounted retinae, counts of FG+ and 
Brn3a+ RGCs were of similar magnitude in eyes with intact optic nerves and were similarly 
reduced after ONC. Larger differences in RGC number were detected between intact and 
ONC groups when images were taken closer to the optic nerve head. In radial sections, 
Brn3a did not stain astrocytes, macrophages/microglia or amacrine cells, whereas βIII-
tubulin and Islet-1 did localize to amacrine cells as well as RGCs. The numbers of βIII-
tubulin+ RGCs was greater than Brn3a+ RGCs, both in retinae from eyes with intact optic 
nerves and eyes 21 days after ONC. Islet-1 staining also overestimated the number of RGCs 
compared to Brn3a, but only after ONC. Estimates of RGC loss were similar in Brn3a-
stained radial retinal sections compared to both Brn3a-stained wholemounts and retinal 
wholemounts in which RGCs were backfilled with FG, with sections having the added 
advantage of reducing experimental animal usage. 
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Introduction 
Retinal ganglion cells (RGCs) populate the ganglion cell layer (GCL) of the retina, although 
in some species a few are found in the inner nuclear layer (INL; displaced RGCs)[1]. All rat 
RGC axons become myelinated at the lamina cribrosa[2,3], project centripetally in the optic 
nerve, partially decussate in the chiasma and synapse in the lateral geniculate body, 
superior colliculus, hypothalamus and pretectal area[3]; a few non-/thinly-myelinated 
peptidergic axons course centrifugally in the optic nerve[4]. Accurate estimates of the total 
number of RGCs are compromised by counting errors engendered by: (1), the presence of 
astrocytes and displaced amacrine cells, estimated to contribute up to 50% of cells in the 
GCL[5,6] and which co-localize with many markers used to identify RGCs[7-9]; (2), RGCs 
displaced into the INL[1]; and (3), a progressive decrement in RGC density from the centre 
of the retina to the periphery[10]. 
Techniques aimed at overcoming these confounding issues include: (1), use of optimal 
detection and sampling methods; (2), counting myelinated RGC axons in the optic nerve; (3), 
using phenotypic antibody markers with exclusive affinity for RGCs; (4), transfecting RGCs 
with green fluorescent protein under control of the Thy-1 promoter; and (5), back filling 
exclusively RGCs with retrogradely transported axon tracers such as FluoroGold (FG) 
injected into an optic nerve or both superior colliculi, for which 98% of RGC project to[3,11-
13]. The precision of estimates of total RGC numbers from either retinal sections or 
wholemounts relies on the sampling method used. In wholemounts, the location of standard 
sampling areas along superior, inferior, temporal and nasal radii is designed to account for 
declining RGC/mm2 at increasing radial distances. In retinal sections, sampling of RGC/mm 
over a standard length of the GCL in matching sections between animals is required and 
consistency is best achieved by counting RGCs in radial retinal sections through the optic 
nerve head. For wholemounts, total absolute counts of RGC number is possible[10] yet may 
be erroneous if calculated from samples in which the spatial differences in RGC density are 
not taken into account when correcting for total retinal area, or if the retina is not dissected 
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accurately. Nonetheless, in RGC viability studies it is generally accepted that retinal 
wholemount and sectional quantitative data give acceptable estimates of percentage 
differences in RGC numbers between treatment and control groups.  
Myelinated axon counts from the optic nerve yield good estimates of the total number of 
RGCs in the retina[14], but monoaminergic small diameter efferent axons with thin myelin 
sheaths[4] are difficult to differentiate from the axons of small RGCs and thus total 
myelinated axon counts overestimate RGC frequency. The use of antibody phenotypic 
markers to identify RGCs, such as βIII-tubulin[15,16], Islet-1[7], Thy-1[17] and Brain-Specific 
Homeobox/POU Domain Protein 3A (Brn3a)[18] is critically dependant on antibody 
specificity. Thy-1 is down-regulated in RGCs in the diseased retina[19] where this antibody 
underestimates RGC number and βIII-tubulin and Islet-1 antibodies both cross-react with 
ligands expressed by amacrine cells[7-9,15] which are less likely to die than RGCs after 
ONC[20], and thus both antibodies exaggerate RGC survival in cases of e.g. glaucoma and 
optic nerve neuritis. By contrast, Brn3a exclusively stains RGCs by binding to a RGC 
specific nuclear epitope[18] with some exceptions such as the intrinsically photosensitive 
RGC that are found to be Brn3a-[21]. Transfection of RGCs with the green fluorescent 
protein gene (gfp), using the Thy-1 promoter is a function of transfection efficiency and the 
number of cells labelled is rarely absolute, e.g. intravitreal injected adeno-assosciated virus 
(AAV) vectors transfect < 85% RGCs[22].  
Back filling all RGCs with FG requires either bilateral injection into the superior colliculi to 
capture both contralateral and ipsilateral RGC projections[11,23], or unilateral injection into 
the optic nerve[3,24]. The technique has the potential drawbacks of: (1), gap junctional 
transfer of tracer between coupled cells in the GCL[12] (although transfer takes significantly 
longer into amacrine cells than into RGCs); (2), incomplete uptake of tracer by RGC axons 
at the site of injection; (3), possible toxicity[25]; (4), erroneous counting of tracer-filled 
macrophages/microglia which have phagocytised dying/dead FG+ RGC[26]; and (5), the lack 
of persistence of FG in neuronal cytoplasm[27], including RGCs 3 weeks after administration 
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to the superior colliculus[11]. Since 2.5-4.2% of albino/hooded rat RGC axons project 
ipsilaterally to the superior colliculus[21], respectively, FG retrograde transport after injection 
of one superior colliculus underestimates RGC numbers in the contralateral retina in this 
species[28]. 
Another disadvantage of labelling RGCs with FG in retinal whole mount analysis is that the 
entire retina and optic nerve are used to generate the labelled cells leaving no tissue for 
extending the analysis to include correlative axon counts in the optic nerve and wider cellular 
and molecular evaluations of treatments, making retinal section analysis more efficient both 
in terms of data acquisition and animal usage[7,9,24]. However, it is not clear how reliable 
counting RGCs in retinal sections is compared to wholemounts where a much larger sample 
of the retina is analysed. 
The present study aimed to define and compare the reliability of RGC counting methods 
including FG RGC back-filling and immuno-staining with the commonly used phenotypic 
markers βIII-tubulin, Islet-1 and Brn3a in rat retinal wholemounts and radial sections to 
determine the most reliable estimates of RGC loss after induction of RGC death by ONC. 
Materials and Methods 
All reagents were purchased from Sigma (Poole, UK) unless otherwise specified. 
Experimental design 
The left optic nerve in a total of 12 rats was crushed (ONC), the right optic nerve remained 
intact (controls). Animals were separated into 2 groups (Table 1), each of 6 rats, which were 
all euthanized on day 21 after ONC. In Group 1, FG was injected into the proximal segment 
of both optic nerves of each rat at day 19 and, 48h later, FG back-filled RGCs, along with 
Brn3a-stained RGCs were counted in retinal whole mounts. Group 1 comprised retinae from 
right eyes with an intact optic nerve (Group 1a) and retinae from left eyes that received an 
ONC (Group 1b). In Group 2, βIII-tubulin-, Islet-1- and Brn3a-stained RGCs were counted in 
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radial sections of the retinae through the optic disk and double stained for astrocytes using 
glial fibrillary acidic protein (GFAP) amacrine cells using syntaxin-1[29,30], and 
macrophages/microglia using ED1 (Table 2). Group 2 comprised retinae from right eyes with 
an intact optic nerve (Group 2a) and retinae from left eyes that received an ONC (Group 2b). 
Group 1 (6 rats) 
RGC counted in 
wholemounted 
retinae 
Intact optic nerve Group 1a (6 eyes) 
Optic nerve crush Group 1b (6 eyes) 
Group 2 (6 rats) 
RGC counted in 
radial retinal sections 
Intact optic nerve Group 2a (6 eyes) 
Optic nerve crush Group 2b (6 eyes) 
Table 1: Animal grouping 
Animals 
All animal procedures were performed in strict accordance to the UK Home Office Animals 
Scientific Procedures Act, 1986 and approved by the University of Birmingham Ethical 
Review Sub-Committee. Twelve adult female Sprague Dawley rats weighing 150-200g (8-10 
weeks; Charles River, Kent, UK) were housed in conditions of 21°C and 55% humidity under 
a 12h light and dark cycle, given food/water ad libitum and supervised constantly by trained 
staff. Anaesthesia was induced with 5% Isoflurane/1.5l per min O2 (National Veterinary 
Supplies, Stoke, UK) and maintained at 3.5% during surgery. 
Surgical procedures 
After anaesthetic induction as described above and a subcutaneous injection of 
buprenorphine (0.1ml/100g; National Veterinary Supplies) animals were secured in a head-
holding frame. Intraorbital left ONC was performed in Group 1b and 2b 8-10 week old rats as 
described previously[31]. Briefly, the optic nerve was exposed and crushed using forceps 
1mm posterior to the lamina cribrosa, completely closed around the optic nerve for 5 
seconds, without damaging the central retinal artery (confirmed by lack of ischemia in eyes 
7-21 days after ONC). After surgery, animals were placed in warmed (30°C) recovery cages 
and closely monitored until the return of normal behaviour, when they were transferred to 
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home cages. Two days before tissue harvest, all Group 1 animals were re-anaesthetised 
and the optic nerves re-exposed as above and 2µl of 4% FG solution (Biotium, Hayward, 
CA) in sterile phosphate-buffered saline (PBS) was injected directly into the right and left 
nerves distal to the lamina cribrosa (proximal to the crush site in the left optic nerves in 
Group 1b), using a glass micropipette, produced in-house from a glass capillary rod (Harvard 
Apparatus, Kent, UK) using a Flaming-Brown micropipette puller (Sutter Instruments, 
Novato, CA). The injected FG is incorporated into axons and retrogradely transported 
axonally to RGC somata. 
Tissue preparation 
Group 1 rats were euthanized at 21 days by rising concentration of CO2. After removal of the 
cornea and lens, the residual eye cups were immersion fixed in 4% paraformaldehyde (PFA; 
TAAB, Reading, UK) in PBS for 2h at 4oC before the retinae were removed and flattened 
onto Superfrost glass slides (Superfrost Plus, Fisher Scientific, Pittsburgh, PA) facilitated by 
4 equidistant radial cuts into the peripheral retina. Wholemounts were 
immunohistochemically stained immediately at room temperature. 
Group 2 rats were euthanized at 21 days by rising concentration of CO2 and perfused 
intracardially with 4% PFA in PBS. Eyes were dissected and immersion fixed in 4% PFA in 
PBS for 2h at 4°C and cryoprotected by sequential immersion in 10%, 20% and 30% 
sucrose solution in PBS, each for 24h with storage at 4°C. Eyes were orientated to permit 
radial sectioning and embedded using optimal cutting temperature embedding medium 
(Thermo Shandon, Runcorn, UK) in peel-away moulds (Agar Scientific, Essex, UK) by rapid 
freezing under crushed dry ice and stored at -80°C. Eyes were sectioned radially on a 
cryostat microtome (Bright, Huntingdon, UK) at -22°C at a thickness of 20µm and sections 
mounted on positively charged glass slides. Radial eye sections containing the optic disk 
and thus sectioned at a consistent axis were utilized for subsequent analysis. Sections were 
stored at -20C°. 
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Immunohistochemistry 
Wholemounted retinae from Group 1 rats were permeabilized in 0.5% Triton x-100 in PBS 
for 15min at -70oC before washing with room temperature 0.5% Triton x-100 for a further 
15min. Retinae were incubated with primary antibodies diluted in wholemount antibody 
diluting buffer (wADB; 2% bovine serum albumin, 2% Triton x-100 in PBS) overnight at 4oC 
and, the following day, were washed 3 x 10min in PBS and incubated with secondary 
antibodies in wADB for 2h at room temperature. After 2h, retinae were washed for 3 x 10min 
in PBS and mounted with the GCL uppermost on glass slides. Slides were allowed to air dry 
before mounting in Vectorshield medium (Vector Laboratories, Peterborough, UK) and 
applying cover slips. The antibodies used in this staining are detailed in Table 2. 
Antigen Specificity Host species Dilution Supplier 
Catalogue 
no. 
βIII-tubulin (sections) Monoclonal Mouse 1:500 Sigma #T8660 
Brn3a (sections) Polyclonal Goat 1:200 Santa Cruz (Santa Cruz, CA) #SC-31984 
Islet-1 (sections & 
wholemounts) 
Polyclonal Rabbit 1:200 Abcam (Cambridge, UK) #ab20670 
Brn3a (wholemounts) Polyclonal Goat 1:100 Santa Cruz (Santa Cruz, CA) #SC-31984 
Syntaxin-1 Monoclonal Mouse 1:200 Abcam #ab3265 
GFAP Monoclonal Mouse 1:200 Sigma #G3893 
ED1 Monoclonal Mouse 1:200 Serotec (Oxford, UK) #MCA341R 
Mouse IgG (Fluor 488) Polyclonal Donkey 1:400 Molecular probes (Paisley, UK) #A-21202 
Rabbit IgG (Fluor 488) Polyclonal Donkey 1:400 Molecular Probes #A-21206 
Rabbit IgG (Fluor 594) Polyclonal Donkey 1:400 Molecular Probes #A-21207 
Goat IgG (Fluor 594) Polyclonal Donkey 1:400 Molecular Probes #A-11058 
Table 2: Antibodies used in immunohistochemistry 
Mounted radial retinal sections through the optic nerve head from Group 2 rats were 
equilibrated to room temperature, hydrated in PBS for 2 X 5min, permeabilized in 0.1% 
Triton x-100 in PBS for 20min at room temperature and washed for 2 X 5min in PBS before 
encircling with a hydrophobic PAP pen (Immedge pen; Vector Laboratories). Non-specific 
protein binding sites were blocked by incubating sections in blocking buffer (75µl; 0.5% 
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bovine serum albumin (g/ml), 0.3% Tween-20, 15% normal goat/donkey serum (Vector 
Laboratories) in PBS) in a humidified chamber for 30min at room temperature, drained and 
incubated with primary antibodies diluted in antibody diluting buffer (ADB; 0.5% bovine 
serum albumin, 0.3% Tween-20 in PBS) overnight at 4°C. The following day, retinal sections 
were washed for 3 X 5min in PBS and incubated with secondary antibodies diluted in ADB 
for 1h in a hydrated incubation chamber at room temperature and then washed for 3 X 5min 
in PBS, mounted in Vectorshield mounting medium containing DAPI (Vector Laboratories) 
and stored at 4°C before microscopic analysis. The antibodies used in this staining are 
detailed in Table 2. Omission of primary antibody was used as a staining control. 
Microscopy and analysis 
For Group 1 retinal wholemounts, images were photographed from 3 different regions from 
each retinal quadrant (as detailed in Fig. 1) using a Zeiss Axioplan-2 fluorescent microscope 
(Carl Zeiss, Ltd., Hertfordshire, UK). Images were captured at 200X magnification using an 
Axiocam HRc camera (Carl Zeiss, Ltd.) and all images equivalently contrast enhanced using 
Photoshop CS3 (Adobe Systems, Inc., San Jose, CA). The experimenter was blinded to 
treatment group and retinal region during counting of total numbers of Brn3a+ and FG+ cells 
(total= 3 counts/quadrant, 12 counts/retina and 6 retinae from 6 different animals per 
treatment group) observed in each 0.260mm2 imaged area. The mean number of 
RGCs/image was calculated from a mean count at each of the 3 radial distances as well as 
a mean composite count over all 3 distances. 
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Figure 1: Sampling method for the counting of RGCs in Group 1 wholemounts (A) and 
Group 2 tissue sections (B). RGC counts in retinal wholemounts were made in sampling 
boxes (0.260mm2) along quadrant radii at 1.5mm, 2.5mm and 3.5mm from the optic nerve 
head (white boxes; A). RGCs were counted in sections over 250µm length regions at a 200-
300µm distance from the centre of the optic nerve in radial retinal sections (white lines; B). 
For panel A, Brn3a (red) was used to stain the retinal wholemount and RGCs (scale bar: 
1mm). For panel B, Brn3a (green) was used to stain RGCs, GFAP (red) to stain glia and 
DAPI (blue) was used as a nucleus stain (scale bar: 250µm).  
 
For Group 2 retinal sections, images were photographed as detailed above and analysed by 
an operator blinded to treatment groups. Brn3a+, βIII-tubulin+ and Islet-1+ RGCs were 
counted in 20µm-thick radial sections of the retina, along a 250µm linear region of the GCL, 
either side of the optic nerve head (Fig. 1). Four sections/retina and 6 retinae from 6 different 
animals per treatment group were quantified. As sectioned tissue inevitably included split 
RGC nuclei, these were only included in the counts if the sizes of Brn3a+//Islet-1+ stained 
nuclei were similar to the co-localised DAPI+ nuclei. Changes in soma/nuclear size have not 
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been reported after ONC[32], therefore, although this technique would be ineffective at 
calculating absolute RGC numbers, any inaccuracies would apply equally to both conditions 
and thus would not impede reliable comparisons of RGC loss between groups. 
Statistics 
All statistical tests were performed using SPSS 17.0 (IBMM SPSS, Inc., Chicago, IL) and 
data were presented as mean ± standard error of the mean (SEM). The Shapiro-Wilk test 
was used to ensure all data were normally distributed before applying a one-way analysis of 
variance (ANOVA) with a Tukey post-hoc test. Statistical differences were considered 
significant at p values < 0.05. 
At the end of the study, a power calculation was performed to determine the required optimal 
animal numbers per treatment group for animal Group 1 and 2. Power calculations were 
performed using G*Power[33] with the following parameters: α error probability (P value) of 
0.05, power (1 - β error probability) of 0.95 and effect size of 1.32, 2.77 and 7.64 which 
relates to 10%, 20% and 50% RGC death (as determined by the program) respectively 
compared to intact counts of 17.83 RGC/250µm of retina.  
Results 
Group 1 rats 
FG+/Brn3a+ RGCs in retinal wholemounts 
In the retinae of Group 1a eyes (intact optic nerve), mean numbers/mm2 of Brn3a+ and FG+ 
RGCs were 869.7 ± 30.6 and 971.7 ± 67.0, respectively (Fig. 2). In the retinae of Group 1b 
eyes (21 days after ONC), mean numbers/mm2 of Brn3a+ and FG+ RGCs were significantly 
reduced (P<0.05) compared to Group 1a values (83.8 ± 15.0 and 100.9 ± 13.8, 
respectively). In Group1a retinae, the density of RGCs decreased towards the periphery, 
reflected by a mean number/mm2 of 1073.1 ± 21.9, 926.1 ± 39.5 and 644.7 ± 69.1 Brn3a+ 
RGCs and 1209.9 ± 75.0, 1036.4 ± 73.3 and 629.0 ± 35.3 FG+ RGCs at 1.5mm, 2.5mm and 
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3.5mm from the centre of the optic nerve, respectively. RGC number was significantly less 
(P<0.05) in Group 1b retinae compared to Group 1a retinae with mean counts of 92.9 ± 
19.9, 79.3 ± 15.5, 79.2 ± 11.3 Brn3a+ RGCs and 119.1 ± 17.3, 95.8 ± 15.6, 88.1 ± 10.3 FG+ 
RGCs at 1.5mm, 2.5mm and 3.5mm from the centre of the retina, respectively.  
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Figure 2: Brn3a+ and FG+ RGC counts in Group 1 wholemounted retinae. 
Immunohistochemically stained wholemounted retina, stained for Brn3a (red; Ai and Aii) and 
FG (gold; Aiii and Aiv; photographs taken in the same field, respectively), taken from Group 
1a animals (intact optic nerve; Ai and Aiii) and Group 1b animals (21 days after ONC; Aii 
and Aiv). All images are representative of the 12 images taken per retina from 6 different 
animals (scale bar: 50µm). In (B), the mean number of Brn3a+ and FG+ RGCs in a 1mm2 
region, from Group 1a and Group 1b rats, calculated as an composite average of 12 images, 
or an average of 4 images taken at 1.5mm, 2.5mm and 3.5mm from the optic nerve head. 
Asterisks indicate significant difference at p<0.01 between the ONC counts and their 
respective Group1a controls. 
 
FG/Brn3a double staining in retinal wholemounts of Group 1a 
In the retinae of Group 1a eyes (intact optic nerve), quantification of RGCs double staining 
for Brn3a and FG revealed that 2.0 ± 0.15% of Brn3a+ RGCs were FG- and 12.1 ± 0.7% of 
FG+ RGCs were Brn3a-. These data confirm that Brn3a is a specific marker of RGCs. 
Group 2 rats 
Brn3a+, βIII-tubulin+ and Islet-1+ RGCs in radial retinal sections 
The somata, dendrites and axons of RGCs were stained with βIII-tubulin in the GCL, inner 
plexiform layer and nerve fibre layer, respectively, and Islet-1-stained nuclei were present in 
the GCL as well as in the INL, whilst Brn3a exclusively stained RGC nuclei in the GCL. 
In Group 2a retinae (intact optic nerve), the numbers/mm of Brn3a+, Islet-1+ and βIII-tubulin+ 
RGCs in the GCL were 71.3 ± 2.2, 72.3 ± 1.8 and 83.6 ± 1.9, respectively (Fig. 3). In Group 
2b retinae (21 days after ONC), the numbers/mm of Brn3a+, Islet-1+ and βIII-tubulin+ RGCs 
in the GCL were 6.7 ± 0.7, 17.0 ± 1.3 and 27.4 ± 0.9, respectively; which were all 
significantly different (P<0.001) from the respective Group 2a counts (Fig. 3). 
The number of βIII-tubulin+ RGCs counted in the GCL was significantly reduced (P<0.001) in 
Group 2b retinae when compared to Group 2a retinae, but remained significantly higher 
(P<0.05) than the number of either Islet-1+ or Brn3a+ RGCs in the GCL of Group 2b retinae. 
Similarly, the number of Islet-1+ RGCs in the GCL was significantly reduced 21 days after 
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ONC, but the number was significantly higher (P<0.05) than the number of Brn3a+ RGCs 
counted in the GCL after ONC. These data demonstrate that βIII-tubulin and Islet-1 
overestimate RGC numbers. 
 
Figure 3: Brn3a+, Islet-1+ and βIII-tubulin+ RGC counts in Group 2 radial retinal sections 
from Group 2a eyes (intact optic nerves) and Group 2b eyes (21 days after ONC). 
Immunohistochemically stained 20-µm-thick radial sections of retina through the optic nerve 
head, stained for βIII-tubulin (green; Ai and Aii) or Brn3a (green) and Islet-1 (red; Aiii and 
Aiv), taken from Group 2a eyes (Ai and Aiii) and Group 2b eyes (Aii and Aiv) with the 
ganglion cell layer (GCL) labelled. All images are representative of the two images/section, 
four sections/retina, and six retinae prepared from six different animals/group. DAPI was 
used as a nucleus stain (scale bar: 15µm). In (B), the number of Brn3a+, Islet-1+ and βIII-
tubulin+ cells, in a 1mm linear region of the GCL from Group 2a/2b eyes. Asterisks indicate 
significant difference at p<0.05 between groups (ONC and intact) and black lines indicate 
significant difference at p<0.05 within groups. 
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Co-localization of Brn3a+, βIII-tubulin+ and Islet-1+ RGCs with GFAP, Syntaxin-1 and 
ED1 in radial retinal sections 
GFAP+ astrocytes were a distinct population of cells in the GCL that did not stain with Brn3a, 
Islet-1 or βIII-tubulin. Syntaxin-1+ amacrine cells in the INL and GCL were Brn3a-, although 
some were Islet-1+ and βIII-tubulin+ (Fig. 4). ED1+ stained sparsely distributed 
macrophages/microglia throughout Group 2a retinae, which did not stain with Brn3a-, Islet-1- 
or βIII-tubulin. These data suggest that the overestimation of RGC numbers by βIII-tubulin 
and Islet-1 staining is due to the staining and subsequent counting of amacrine cells 
displaced into the GCL. 
 
Figure 4: Expression of Brn3a, Islet-1 and βIII-tubulin in radial retinal sections and co-
localisation of staining for the astrocyte marker GFAP, the amacrine cell marker Syntaxin-1 
and the macrophage/microglia marker ED1. Immunohistochemically stained 20-µm-thick 
radial sections of retina, stained for Brn3a (green; Ai, Aiv and Avii), Islet-1 (green; Aii, Av 
and Aviii), βIII-tubulin (green; Aiii, Avi and Aix), GFAP (red; Ai, Aii and Aiii), Syntaxin-1 
(red; Aiv, Av and Avi) and ED1 (red; Avii, Aviii and Aix), taken from Group 2a eyes (intact 
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optic nerve), with the outer nuclear layer (ONL), inner nuclear layer (INL) and ganglion cell 
layer (GCL) labelled, insert showing higher power image of the GCL. All images are 
representative; DAPI (blue) was used as a nucleus stain (scale bar: 50µm; inset scale bar: 
25µm). 
 
Group 1 and 2 rats 
Estimates of RGC death were similar in Group 1 Brn3a/FG-stained retinal 
wholemounts and Group 2 Brn3a-stained radial sections 
In Group 2 radial retinal sections, the percentage death of Islet-1+/βIII-tubulin+ RGC detected 
was 76.5 ± 1.5% and 67.0 ± 1.6%, respectively, which was significantly lower (P < 0.05) than 
that revealed by Brn3a staining (90.6 ± 0.9%) as well as that estimated after Brn3a/FG 
staining of retinal wholemounts (90.2 ± 1.8% and 89.3 ± 1.6%, respectively; Fig. 5). These 
data show that Brn3a-stained radial sections report the same percentage RGC death as 
Brn3a-/FG-stained wholemounts demonstrating that both techniques reliably quantify RGC 
loss. In contrast, Islet-1-/βIII-tubulin-stained radial sections overestimate the number of 
surviving RGCs after ONC and thus underestimate the percentage of RGC loss. 
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Figure 5: The mean percentage of RGC loss 21 days after ONC in Group 1 and Group 2 
rats. Asterisks indicate significant difference at P<0.05 compared to Brn3a+ RGCs in 
sections and Brn3a+/FG+ RGCs in wholemounts (n=6). 
 
Brn3a-stained Group 1 wholemounts and Group 2 radial sections detect as low as 
10% RGC death 
Using data derived from this experiment, a power calculation was performed to determine 
that, in order to detect 50% RGC death at P<0.05, 3 animals/group are required, to detect 
20% RGC death at P<0.05, 5 animals/group are required and to detect 10% RGC death at 
P<0.05, 16 animals/group are required. These data suggest that even as low as 20% RGC 
death can be detected in radial stained sections with acceptable animal numbers. 
Discussion 
Reliable measures of percentage RGC survival in experimental degenerative retinal 
conditions including glaucoma[34] and optic nerve neuropathies[35] are essential to evaluate 
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the efficacy of novel therapeutic agents designed to treat these disorders. Pertinent to this is 
the identification of good phenotypic markers for RGCs. This study provides evidence that, in 
determining percentage RGC loss in rats, estimates from radial sections of retinae are 
similar to estimates from wholemounted retinae. Furthermore, the data reinforce the notion 
that Brn3a antibodies are the most reliable phenotypic markers of RGCs both in 
wholemounts and sections, whereas βIII-tubulin and Islet-1 antibodies stain amacrine cells in 
the GCL, giving underestimates of RGC loss.  
Our findings that Brn3a antibodies and FG tracer label statistically similar numbers of RGCs 
in wholemounted retinae, both before and after ONC-induced RGC death are consistent with 
the reported 95% co-localization of Brn3a and FG staining in RGCs[18], further emphasising 
the utility of Brn3a antibodies as a reliable RGC marker. The percentage of Brn3a+ cells that 
were FG- was 2.0%, which is comparable to the 4.4% previously reported[18]. FG, a weak 
base, freely diffuses into intracellular vesicles where it raises the pH, making the vesicle 
impermeable, trapping the FG within; the vesicle is then transported along the cytoskeleton 
of the axon[36]. A likely explanation for the presence of FG-Brn3a+ RGCs is that FG uptake 
into RGC axons is 98% efficient. In this study the percentage of FG+ cells that were Brn3a- 
was 12.1%, slightly more than the 3.4% previously reported[18], a figure that is probably 
explained by the exclusion of FG+/Brn3a- macrophages/microglia from the data in the Nadal-
Nicolas study. By contrast, in the present study, all cells that were positive for their 
respective phenotypic markers were counted and included and thus we can postulate (but 
not be certain) that a small proportion of these FG+ cells were macrophages/microglia. In 
Figure 2, FG+ and Brn3a+ images were taken in the same field but co-localization appears 
reduced after ONC, likely due to surviving FG+/Brn3a- macrophages the frequency of which 
is increased after RGC death. Although RGC number decreased with increasing distance 
from the optic nerve head (1.5mm, 2.5mm and 3.5mm), the number of RGCs surviving after 
ONC did not change with distance (Fig. 2B.), and thus counts closest to the optic nerve head 
yielded the biggest relative differences. This is explained by the homogenous RGC death 
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occurring after axotomy/ONC[10] whereas the sectorial death seen in laser-induced ocular 
hypertension models of glaucoma[37-40] requires sampling from multiple distances to 
ensure accuracy in determining the extent of RGC loss. The counts made from 4 and 12 
images had similar SEM, revealing the strength of the sampling method.  
One limitation of this study is that eyes with intact optic nerves (Group 1a, 2a) contralateral 
to the ONC eyes (Group 1b, 2b) were used as controls. It has previously been shown that 
ocular hypertension induces microglia activation in eyes contralateral to the injury[41] as well 
as a decrease in astrocytes and activation of Müller cells[42], with these results partially 
replicated for unilateral ONC[43]. However, these changes have not been correlated with 
RGC number[42] and equally, the RGC loss observed in our study 21 days after ONC (when 
compared to contralateral eyes) is equivalent to losses reported in the published 
literature[3,35,44] leading us to assume that any contralateral effects instigated by the 
unilateral ONC had negligible effects on RGC numbers. An added value of contralateral eye 
counts is the resulting reduction in animal usage. 
In wholemounted Group 1 retinae, Brn3a is preferred to FG as a RGC marker, since FG 
delivery into the optic nerve for retrograde transport to RGC somata requires further surgery 
under anaesthesia. Counts of RGCs with 4 sampling areas each 1.5mm from the optic nerve 
head gave reliable estimates of RGC number in which SEM values where similar to when 12 
images/samples were used. In wholemounts, βIII-tubulin-stained axons and dendrites which 
obscured many RGCs, leading to their exclusion from the count (Fig. S1). In Islet-1-stained 
wholemounts, the high background staining of the INL (Fig. S1) made RGC counting difficult 
and excluded consistent 4-image sampling of some retinae. 
Retinal wholemounts restricts the use of the retina to a limited number of antibody stains[45] 
and renders the tissue unusable for further analysis, such as evaluating the effects of 
treatments on other proteins and cells as well as retrieving morphological data such as 
retinal detachment or the location of grafted cells. By contrast, radial sections allow all of 
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these data to be obtained from multiple sections from the same eyes with no loss of fidelity 
in RGC quantification. Of note, the homogenous and diffuse loss of RGCs seen after 
ONC/axotomy[10] makes sampling around the optic nerve head in sections a reliable 
estimate of RGC loss, whereas in models such as glaucoma where the loss is sectorial[37-
40], expanded sampling is required to include sections throughout the eye, counting in 
regions at multiple distances from the optic nerve head. 
We tested Brn3a[18,24], Islet-1 and βIII-tubulin[7,9,24] as presumptive phenotypic RGC 
markers. Compared to Brn3a, βIII-tubulin-stained significantly more cells in the GCL both 
before and after ONC-induced RGC death, which we and others[8] interpret as being due to 
labelling of amacrine cells in addition to RGCs. Thus this antibody over estimates the 
numbers of RGCs both in Group 1a/2a animals (intact optic nerve) and even more so in 
Group 1b/2b animals (21 days after ONC) where the ratio of amacrine cells to RGCs is 
increased as RGCs are preferentially lost[20]. Compared to the Brn3a antibody, the Islet-1-
stained similar numbers of cells before ONC but significantly more after ONC (although still 
significantly less than with βIII-tubulin staining after ONC). Since the Islet-1 antibody stains 
RGCs and amacrine cells[9], and more displaced amacrine cells survive relative to RGCs in 
the GCL 21 days after ONC[20], Islet-1 antibody will overestimate RGC numbers in 
comparison to Brn3a after ONC-induced RGC death. 
To determine if counts from sections are as reliable as from wholemounts in quantifying 
RGC death, we compared the percentage loss of RGCs between all methods used in this 
study. The published figures of 90% RGC death 21 days after ONC[24,35,44] are similar to 
those seen in this study with Brn3a-/FG-stained wholemounts and with Brn3a-stained radial 
retinal sections, confirming that counts made in retinal sections are as reliable as those 
made in retinal wholemounts. Considering both the small SEM for each mean and the 
results from our power calculation, counts from sections and wholemounts have equal 
fidelity in determining significant differences between groups with as low as 20% difference 
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in RGC number, without the need for significant increases in animal numbers per treatment 
group.  
Conclusions 
We conclude that Brn3a antibody staining of radial retinal sections is a preferred method for 
estimating RGC frequency when compared to techniques using retinal wholemounts in 
rodent models of ocular disease. The method avoids both the additional surgery needed for 
injection of FG and the sacrifice of further molecular and morphological retinal analysis, 
potentially reducing animal usage and associated costs. We show that cell counts from 
retinal sections are as reliable as those from retinal wholemounts and have equivalent 
fidelity in determining RGC loss between control and experimental groups. 
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Figure S1: Islet-1- and βIII-tubulin-stained wholemounted retinae from Group 1a eyes (intact 
optic nerve). Immunohistochemically stained wholemounted retina stained for Islet-1 (green; 
Ai) or βIII-tubulin (green; Aii), taken from Group 1a eyes. All images are representative of 
the 12 images taken per retina from 6 different animals (scale bar: 50µm). 
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Abstract 
Purpose 
To investigate the potential therapeutic benefit of intravitreally implanted dental pulp stem 
cells (DPSC) on axotomised adult rat retinal ganglion cells (RGCs) using in vitro and in vivo 
neural injury models. 
Methods 
Conditioned media collected from cultured rat DPSC and bone marrow-derived 
mesenchymal stem cells (BMSC) were assayed for nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) secretion using ELISA. DPSC or 
BMSC were co-cultured with retinal cells, with or without Fc-TrK inhibitors, in a transwell 
system and the number of surviving βIII-tubulin+ retinal cells and length/number of βIII-
tubulin+ neurites were quantified. For the in vivo study, DPSC or BMSC were transplanted 
into the vitreous body of the eye after a surgically-induced optic nerve crush injury. At 7, 14 
and 21 days post-lesion (dpl), optical computerized tomography (OCT) was used to measure 
the retinal nerve fibre layer thickness as a measure of axonal atrophy. At 21 dpl, numbers of 
Brn-3a+ RGCs in parasagittal retinal sections and growth associated protein-43+ axons in 
longitudinal optic nerve sections were quantified as measures of RGC survival and axon 
regeneration, respectively. 
Results 
Both DPSC and BMSC secreted NGF, BDNF and NT-3, with DPSC secreting significantly 
higher titres of NGF and BDNF than BMSC. DPSC, and to a lesser extent BMSC, promoted 
statistically significant survival and neuritogenesis/axogenesis of βIII-tubulin+ retinal cells in 
vitro and in vivo where the effects were abolished after TrK receptor blockade. 
Conclusion 
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Intravitreal transplants of DPSC promoted significant neurotrophin-mediated RGC survival 
and axon regeneration after optic nerve injury. 
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Introduction 
Trauma is the most common cause of central nervous system (CNS) injury with, in America 
alone, 11,000 people a year suffering a spinal cord injury (SCI)1, 80,000 a year suffering 
severe traumatic brain injury2 and between 0.5 to 5.0% of head injuries resulting in traumatic 
optic neuropathy3. Chronic degenerative diseases are another leading cause of CNS 
damage, including glaucoma, a condition that affects retinal ganglion cells (RGCs) and is the 
2nd leading cause of blindness worldwide4. Lost neurons are not replaced and severed axons 
do not regenerate after CNS injury and thus recovery of lost sensory and motor function is 
severely limited.  
The failure of CNS axons to regenerate after injury is partly attributed to a non-permissive 
trophic environment comprised of both a paucity of neurotrophic growth factors and an 
abundance of axon growth inhibitory molecules5. Neurotrophins, a class of neurotrophic 
factors (NTF), include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) 
and neurotrophin-3 (NT-3). They promote regeneration of injured axons and the survival of 
axotomised neurons after binding to the tropomyosin receptor kinase -A, -B and -C (TrK) 
receptors, respectively6. Inhibitory ligands, which derive from degenerate myelin7, 8 and scar 
tissue6, 9 in CNS lesion sites, induce receptor-mediated growth cone collapse of regenerating 
injured axons. 
Thus, inducing changes to the microenvironment of injured neurons/axons to promote 
neuronal survival and disinhibited axon regeneration represents a potential treatment 
approach. The delivery of NTF to neuron somata rather than to the lesion site has proved a 
successful therapeutic strategy6. For example, several studies have successfully promoted 
RGC survival after intravitreal delivery of exogenous NTF to the vitreous after optic nerve 
injury10, 11. To promote a significant effect, however, repeated injections of NTF combinations 
are necessary, which are highly invasive for the patient, indicating that a continuous delivery 
mechanism is preferred12, 13. Moreover, bolus administration of neurotrophins act to down-
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regulate the TrK receptors14, 15, an effect that may be avoided by opting for a lower but 
continuous delivery regime. Cellular therapy is regarded as a promising means of altering 
the trophic environment of damaged CNS neurons such as RGCs. This strategy has met 
with some success, for example, using intravitreally administered fibroblasts genetically 
altered to release NTF combinations16 after optic nerve crush (ONC), which acts as an 
effective model of CNS injury in general and retinal neuron disease in particular6.  
As an alternative to engineered cells, naturally occurring stem cells have been used to 
promote CNS repair, providing a source of either replacement neurons17, 18 or NTF 
combinations that promote endogenous neuron survival and axon regeneration by altering 
the local trophic microenvironment19. Stem cell based CNS studies have increasingly used 
NTF-secreting bone marrow-derived mesenchymal stem cells (BMSC) as a cellular 
therapy20, 21. Moreover, BMSC conditioned medium is neuroprotective in culture22 and 
intravitreal BMSC transplantation is neuroprotective for RGCs after optic nerve injury23 and 
glaucoma24. 
However, an emerging alternative stem cell source is the dental pulp which contains self-
renewing and pluripotent stem cells25. Dental pulp stem cells (DPSC) are isolated from the 
dental pulp of both infant and adult mammalian teeth with relative ease of access and few 
ethical hurdles. Thus, DPSC represent a potential autologous and allogeneic cellular therapy 
for CNS injury, particularly since recent evidence suggests that they are more potent than 
BMSC at promoting functional recovery after spinal cord injury21. Although largely 
uncharacterised, a few studies have explored their potential to play a direct role in neuronal 
replacement due to their neural crest origin26. DPSC differentiate into neurons under defined 
in vitro conditions27, 28 and their integration into the CNS after transplantation has been 
described29. 
Less focus has been given to exploiting DPSC as an indirect NTF therapy, i.e. using DPSC-
derived NTF to promote endogenous CNS neuron survival and axon regeneration. DPSC 
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express mRNA for NGF, glial cell line-derived neurotrophic factor (GDNF) and BDNF30-32. 
When transplanted into the hippocampus, DPSC secrete ciliary neurotrophic factor (CNTF), 
vascular endothelial growth factor, NGF and fibroblast growth factor-2 (FGF-2)33, which 
could explain the findings of Sakai et al, 2012 who demonstrated some functional recovery 
after complete transection of the spinal cord by transplanting DPSC into the lesion site21. 
The authors witnessed both an improvement in locomotory BBB34 scores and axon growth 
into the cell implant and across the lesion site at greater levels than after BMSC transplant. 
This observation, along with the greater expression of neurotrophic factor mRNA by DPSC 
compared to BMSC21 indicates that DPSC produce higher titres of neurotrophic factors 
compared to BMSC. DPSC transplanted into a cerebral infarct site after middle cerebral 
artery occlusion also promoted significant recovery in forelimb sensorimotor function. The 
transplanted DPSC differentiated into astrocyte-like cells suggesting DPSC contributed to 
neural regeneration as a supportive cell through NTF secretion35. 
In the present study, we investigated the neuroprotective and axogenic properties of primary 
adult rat DPSC for axotomised RGCs. We carried out in vitro co-culture studies of DPSC 
with primary adult rat retinal cultures and compared βIII-tubulin+ retinal cell survival and 
neurite outgrowth in these cultures with that in BMSC/retinal cell co-cultures. Using specific 
TrK-Fc fusion protein blockers of the neurotrophin receptors, we determined a βIII-tubulin+ 
retinal cell neuroprotective and axogenic role for DPSC-derived neurotrophins. In addition, 
we used an in vivo model of ONC injury to determine the effects of intravitreal stem cell 
transplantation on Brn-3a+ RGC survival and axon regeneration. Our findings demonstrate 
that DPSC promote RGC survival and axon regeneration through the secretion of 
neurotrophins to a greater extent than do BMSC and hence we propose that DPSC have 
potential as a cellular therapy to treat RGC injury and degenerative disease. 
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Experimental procedures 
All reagents were purchased from Sigma (Poole, UK) unless otherwise specified. 
DPSC isolation and culture 
Three adult male Sprague-Dawley rats weighing 170-200g (Charles River, Kent, UK) were 
housed under Home Office guidelines and killed by “Schedule 1 Methods” before extraction 
of both upper and lower incisors. The dental pulp was removed under sterile conditions in 
DMEM (Life Technologies, Gibco, UK) supplemented with 1% penicillin/streptomycin (P/S), 
sliced into 1mm3 fragments and incubated in 4ml of 0.25% trypsin-EDTA for 30min at 37°C.  
Trypsin was inactivated by adding an equal volume of DMEM containing 1% P/S and 10% 
foetal bovine serum (FBS). A single cell population was obtained by passing the cell 
suspension through a 70µm cell strainer (BD Biosciences, Oxford, UK), which was 
centrifuged at 150xg for 5min. Cell pellets were resuspended in DMEM containing 1% P/S 
and 10% FBS and seeded into T25 flasks (Corning, Amsterdam, NL) in a total volume of 
5ml. Cultures were maintained at 37°C in 5% CO2 and medium was changed 24h after 
seeding, and every 3d thereafter, with cells passaged when 80% confluent using 0.05% 
trypsin. Each animal provided stem cells for separate cultures to supply conditioned medium 
for the ELISA before cells from 3 cultures were pooled for the in vitro co-culture/in vivo 
transplantation experiments. 
BMSC isolation and culture 
BMSC were isolated from femurs removed from the same animals described above. In 
sterile conditions, the ends of the femurs were detached, and the bone marrow flushed with 
10ml of DMEM. Cell aspirates were centrifuged at 150xg for 5min before cells were 
resuspended in DMEM containing 1% P/S and 10% FBS. Cell suspensions were seeded 
into T25 flasks in a total volume of 5ml. Cultures were maintained at 37°C in 5% CO2 and 
medium was changed 24h after seeding and every 3d thereafter, with cells passaged when 
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80% confluent. Each animal provided stem cells for separate cultures to supply conditioned 
medium for the ELISA before cells from 3 cultures were pooled for the in vitro co-culture/in 
vivo transplantation experiments. 
NGF/BDNF/NT-3 ELISA 
To quantify the neurotrophins produced by BMSC and DPSC, conditioned medium was 
taken from cells at passage 2-4, cultured for 48h and assayed using EMAX Immunoassay kits 
(Promega, Southampton, UK) for rat NGF, BDNF and NT-3 as well as CNTF (R&D systems, 
UK) according to the manufacturer’s instructions. Briefly, a standard curve was constructed 
using the provided neurotrophin standards and test samples of conditioned medium at 
varying dilutions were run in duplicate after acid treatment, with neurotrophin concentrations 
extrapolated from the standard curve. 
Retinal cell co-culture 
Cell culture 24-well plates (BD Biosciences) were coated for 60min with 100µg/ml poly-D-
lysine and then for 30min with 20µg/ml laminin. After terminal anaesthesia, eyes were 
removed from 3 male Sprague-Dawley rats weighing 170-200g (Charles River) and the 
retinae minced in 1.25ml of papain (Worthington Biochem, NJ, USA) containing 62.5µl of 
DNase I (Worthington Biochem) and incubated for 90min at 37°C. The retinal cell 
suspension was centrifuged at 300xg for 5min and the pellet resuspended in a solution 
containing 1.35ml of EBSS (Worthington Biochem), 150µl of reconstituted albumin 
ovomucoid inhibitor (Worthington Biochem) and 75µl of DNase I. After adding to the top of 
2.5ml of albumin ovomucoid inhibitor to form a discontinuous density gradient, the retinal cell 
suspension was centrifuged at 70xg for 6min. The resulting retinal cell pellet was 
resuspended in 1ml of supplemented Neurobasal-A (24.2ml Neurobasal-A (Gibco) 
supplemented with 500µl of B27 supplement (Life Technologies, Invitrogen, UK), 62.5µl of L-
glutamine (200mM; Invitrogen) and 125µl of gentamycin (Invitrogen)) and seeded at a 
density of 125,000 cells/800µl in each well of the 24 well plate. 
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DPSC and BMSC were used at passage 2-4 and plated at a density of 50,000 cells/200µl 
into a 0.4µm porous cell culture insert (Millicell, Millipore, UK) that was inserted into each of 
the 24 wells containing retinal cells to give a total volume of 1ml of medium per well. 
Particular wells containing retinal cell cultures were also treated with 5µg/ml TrKA-Fc, TrKB-
Fc and/or TrKC-Fc (single or combinatorial treatments; R&D systems) fusion TrK-specific 
protein inhibitors36 as well as the general kinase inhibitor k252a (50nM). A combination of 
recombinant human NGF, BDNF and NT-3 was also added to selected retinal cell cultures 
(all at 60ng/ml) to act as a positive control. 
Co-cultures were incubated for 4d at 37°C before immunocytochemical staining of retinal 
cells for βIII-tubulin. All experiments were repeated on 3 separate occasions. Each of the 
treatment groups in each of the 3 experimental runs comprised 3 replicate wells containing 
retinal cells harvested from one animal. The DPSC/BMSC tested in each of the 3 
experimental runs represented pooled cells from 3 animals. 
In vivo experimental design 
The experimental design for the in vivo experiment is detailed in Figure 1. Briefly, 18 animals 
(36 eyes) were divided into 6 groups of 6 eyes. The first 6 animals (12 eyes) received a 
bilateral ONC and DPSC transplanted intravitreally, living cells in the right eye and dead 
cells in the left. The next 6 animals (12 eyes) received the same allocation but BMSC were 
transplanted instead of DPSC. The final 6 rats (12 eyes) received a unilateral ONC to the left 
eye, while the right eye served as an intact control. Both eyes in each animal of this group 
received an intravitreal control injection of phosphate-buffered saline (PBS) instead of cell 
suspension to control for the transplantation procedure. Optical coherence tomography 
(OCT) was used to measure retinal nerve fibre layer thickness (RNFL) of animals every 7d, 
including 7d before the surgery and excluding the day of the surgery. Animals were killed at 
21 days after ONC/cell transplantation. 
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Figure 1: Experimental design used for in vivo experiment. Timeline of the in vivo 
experiment detailing the times when the OCT recordings and tissue collections were 
undertaken, in relation to the day of the ONC and DPSC/BMSC transplantation. 
 
Animals 
All animal procedures were performed in strict accordance to the UK Home Office Animals 
Scientific Procedures Act, 1986, ARVO statement for the use of animals in ophthalmic and 
vision research and approved by the University of Birmingham Ethical Review Sub-
Committee. Eighteen adult female Sprague Dawley rats weighing 150-200g (Charles River) 
were housed in conditions of 21°C and 55% humidity under a 12h light and dark cycle, given 
food/water ad libitum and were under constant supervision from trained staff. Anaesthesia 
was induced with 5% Isoflurane/1.5L per minute O2 (National Veterinary Supplies, Stoke, 
UK) and was maintained at 3.5% during surgery. 
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Surgical procedures 
Following anaesthetic induction as described above, a subcutaneous injection of 
buprenorphine (0.1ml/100g; National Veterinary Supplies) was given and the animal secured 
in a head-holding frame. Intraorbital ONC was performed as described previously37. Briefly, 
the optic nerve was surgically exposed and crushed using forceps 1mm posterior to the 
lamina cribrosa with no damage to retinal blood vessels. Immediately after ONC, a glass 
micropipette, produced in-house from a glass capillary rod (Harvard Apparatus, Edenbridge, 
Kent, UK) using a Flaming-Brown micropipette puller (Sutter Instruments, California, USA) 
preloaded with 150,000 cells suspended in 5µl of PBS, was used to inject living or dead cells 
(killed by heating for 30 minutes at 80°C; or PBS alone in controls), into the vitreous of the 
eye. After surgery, animals were placed in heated recovery cages and monitored for 
recovery of normal behaviour, after which they were returned to home cages. 
OCT of RNFL 
Every 7d, including 7d before the surgery but excluding the week of the surgery (Figure 1), 
OCT was performed on rats (anaesthetised as detailed above) using a Spectralis HRA3 
confocal scanning laser ophthalmoscope (Heidelberg Engineering, Heidelberg, Germany). 
OCT images were taken of the retina around the optic nerve head and the in-built software 
was used to segment the gathered images and quantify the RNFL thickness. 
Tissue preparation 
At 21 dpl, animals were given an intraperitoneal injection of 1ml sodium pentobarbital 
(National Veterinary Supplies) and perfused intracardially with 4% paraformaldehyde (PFA; 
TAAB, Reading, UK) in PBS while under terminal anaesthesia. Eyes and optic nerves were 
removed and immersion fixed in 4% PFA in PBS for 2h at 4°C before cryoprotection in 10%, 
20% and 30% sucrose solution in PBS for 24h with storage at 4°C. Eyes and optic nerves 
were then embedded using optimal cutting temperature embedding medium (Thermo 
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Shandon, Runcorn, UK) in peel-away mould containers (Agar Scientific, Essex, UK) by rapid 
freezing under crushed dry ice and were stored at -80°C. After embedding, eyes and optic 
nerves were sectioned on a cryostat microtome (Bright, Huntingdon, UK) at -22°C at a 
thickness of 20µm and 15µm, respectively, and mounted on positively charged glass slides 
(Superfrost Plus, Fisher Scientific, Pittsburgh, USA). Longitudinal optic nerve and 
parasagittal eye sections were left to dry on slides overnight at 37°C before storage at -
30°C. Optic nerve sections were chosen at random for analysis whereas eye sections were 
chosen with the optic nerve head visible. 
Immunohistochemistry 
Mounted tissue sections were equilibrated to room temperature, hydrated in PBS for 2 X 
5min, permeabilized in 0.1% triton x-100 in PBS for 20min at room temperature and washed 
for 2 X 5min in PBS before isolation with a hydrophobic PAP pen (Immedge pen; Vector 
Laboratories, Peterborough, UK). Non-specific protein binding sites in sections were blocked 
by incubation in blocking buffer (75µl; 0.5% bovine serum albumin (g/ml), 0.3% Tween-20, 
15% normal goat/donkey serum (Vector Laboratories) in PBS) in a humidified chamber for 
30min at room temperature and then sections were drained and incubated with primary 
antibody diluted in antibody diluting buffer (ADB; 0.5% bovine serum albumin, 0.3% Tween-
20 in PBS) overnight at 4°C. The following day, slides were washed for 3 X 5min in PBS. 
Tissue sections were then incubated with secondary antibody diluted in ADB for 1h in a 
hydrated incubation chamber at room temperature. After 1h, slides were washed for 3 X 
5min in PBS, mounted in Vectorshield mounting medium containing DAPI (Vector 
Laboratories) and stored at 4°C before microscopic analysis. Antibodies used in this staining 
are detailed in Table 1. 
Immunocytochemistry 
Cells in 24 well plates were fixed in 4% PFA for 10min, washed for 3 X 10min of PBS, 
blocked in blocking solution as described above for 20min and incubated with primary 
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antibody diluted in ADB for 1h at room temperature. After 1h, cells were washed for 3 X 
10min in PBS, incubated with the secondary antibody diluted in ADB for 1h at room 
temperature, washed for 3 X 10min in PBS, mounted in Vectorshield mounting medium 
containing DAPI and stored at 4°C. Antibodies used in this staining are detailed in Table 1. 
Microscopy and analysis 
Fluorescently stained sections were analysed by an operator blinded to treatment groups, 
using a Zeiss Axioplan-2 fluorescent microscope (Carl Zeiss Ltd, Hertfordshire, UK). For 
immunocytochemistry, all retinal cells that were positive for the neuronal marker βIII-
tubulin38, with or without neurites, were counted over each entire well of the 24 well plate, 
with the number of βIII-tubulin+ retinal cells with neurites and the total number of βIII-tubulin+ 
retinal cells being recorded. Neurite outgrowth was measured in images taken at 20X 
magnification using an Axiocam HRc camera (Carl Zeiss Ltd). Each well was divided into 9 
equal sectors and the length of the longest neurite per βIII-tubulin+ retinal cell in each sector 
was measured using Axiovision software (Carl Zeiss Ltd). 
For immunohistochemistry, Brn3a+ RGCs39 were counted in 20µm thick sections of the 
retina, along a 250µm linear region of the ganglion cell layer, stretching out horizontally 
either side of the optic nerve. Four sections per retinae and 6 retinae from 6 different animals 
per treatment group were quantified. 
For in vivo quantification of axon regeneration, 20X magnification images were taken of 
growth associated protein-43 (GAP-43) stained longitudinal sections of the optic nerves and 
composite images were constructed in Photoshop CS3 (Adobe Systems Inc, San Jose, CA, 
USA). Photoshop CS3 was used to contrast enhance selected images to improve the 
visibility of GAP-43+ axons, with all manipulations kept identical across the treatment groups. 
RGC axon regeneration in vivo was quantified in the composite images by counting the 
number of GAP-43+ axons extending across a line set at 90° across the optic nerve at 100, 
200, 400, 800 and 1200µm distal (towards the chiasm) to the centre of the crush site 
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(identified by laminin+ staining) of 6 optic nerves from 6 different animals per treatment group 
and 3 sections per optic nerve. By measuring the diameter of the nerve at each 
measurement point, the number of axons/mm width was calculated. This value was then 
used to derive ∑ad, the total number of axons extending distance d in an optic nerve with 
radius r using the formula described by others40:   
∑𝑎𝑑 = π𝑟2  × 
average number of axons/mm width
section thickness (0.015𝑚m)
 
Statistics 
All statistical tests were performed using SPSS 17.0 and data were presented as mean ± 
standard error of the mean (SEM). The Kolmogorov-Smirnov test was used to ensure all 
data were normally distributed before parametric testing using a one-way analysis of 
variance (ANOVA) with a Tukey post-hoc test. Statistical difference was considered 
significant at p values < 0.05. 
Results 
DPSC secreted NGF, BDNF and NT-3 
DPSC secreted NGF (281 ± 68pg/24h/105 cells), BDNF (1600 ± 338pg/24h/105 cells) and 
NT-3 (270 ± 53pg/24h/105 cells) in culture, as analysed by ELISA (Figure 2). These 
neurotrophic titres were 2-3 fold higher than those detected in conditioned medium from 
BMSC cultures (91.3 ± 24.2, 749 ± 237, 166 ± 46pg/24h/105 cells, respectively) with the 
differences for NGF and BDNF being statistically significant (p<0.05). CNTF was 
undetectable in all samples tested (data not shown). 
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Figure 2: NGF, BDNF and NT-3 secretion from DPSC and BMSC. DPSC and BMSC 
conditioned medium, collected after 48h of cell culture, was assayed using specific ELISAs 
for rat NGF, BDNF and NT-3 (n = 3; Black lines indicate significant difference at p<0.05). 
 
DPSC promoted βIII-tubulin+ retinal cell survival and neuritogenesis in a co-
culture assay 
DPSC promoted a significant (p<0.05) increase in the survival of co-cultured βIII-tubulin+ 
retinal cells (340.3 ± 10.4 cells/well) compared with retinal cells cultured alone (92.7 ± 20.8 
cells/well), co-cultured with BMSC (227 ± 27.6 cells/well) or treated with recombinant human 
NGF, BDNF and NT-3 (278.7 ± 8 cells/well; Figure 3). 
DPSC also promoted a significant (p<0.05) increase in the number of βIII-tubulin+ retinal 
cells with neurites as well as the neurite length (161.6 ± 5.8 µm, 172.7 ± 9.5µm, respectively; 
Figure 3) compared with either retinal cells cultured alone (36 ± 5.2 µm, 22.7 ± 5.2µm) or co-
cultured with BMSC (137.8 ± 2.3 µm, 91 ± 12.6µm; Figure 3). The combination of 
recombinant human NGF, BDNF and NT-3, significantly (p<0.05) increased the number of 
βIII-tubulin+ retinal cells with neurites (142.3 ± 10.1 cells/well) as well as the neurite length 
(155.4 ± 27.4µm) compared with retinal cells cultured alone, or when co-cultured with BMSC 
(p>0.05). 
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Figure 3: Effects of DPSC and BMSC on βIII-tubulin+ retinal cells in vitro. βIII-tubulin+ retinal 
cells, cultured either alone (A i), with exogenous neurotrophins (A ii), with BMSC (with or 
without TrK inhibitors, A iii and A iv, respectively) or with DPSC (with or without TrK 
inhibitors, A v and A vi, respectively). All images are representative of the entire culture, 9 
separate culture wells per treatment with every 3 wells using a different animal (scale bars = 
100µm). The number of surviving βIII-tubulin+ retinal cells (B), number of βIII-tubulin+ retinal 
cells with neurites (C) and the length of the longest βIII-tubulin+ retinal cell neurite (D) when 
retinal cells were co-cultured with BMSC (blue bars), DPSC (red bars), exogenous 
neurotrophins (green bars) or alone (purple bars). Black lines indicate significant difference 
at p<0.05. The effects of TrKA, B and C Fc-inhibitors as well as K252a on βIII-tubulin+ retinal 
cell survival and neuritogenesis in DPSC and BMSC co-cultures are shown (points marked 
with an * indicate significant difference from uninhibited cultures at p<0.05). 
 
Fc-TrK receptor blockers attenuated the survival and neuritogenic effects of 
DPSC 
The number of βIII-tubulin+ retinal cells surviving in DPSC co-cultures (340.3 ± 10.4 
cells/well) was significantly (p<0.05) decreased after treatment with Fc-TrKA (182.7 ± 16.4 
cells/well), Fc-TrKB (165.3 ± 3 cells/well) and Fc-TrKC (193 ± 17.1 cells/well) used alone or 
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in combination (99.3 ± 9 cells/well, Figure 3). In BMSC co-cultures, βIII-tubulin+ retinal cell 
survival (227 ± 27.6 cells/well) was significantly (p<0.05) reduced with Fc-TrKA (145.3 ± 5.4 
cells/well), Fc-TrKB (138 ± 5.5 cells/well) or Fc-TrKA, B and C together (85.7 ± 17.1 
cells/well), but not after adding Fc-TrKC (158.3 ± 10.3 cells/well; p>0.05).  
Fc-TrKA, B and C used individually significantly (p<0.05) decreased both the number of 
neurite bearing cells (84 ± 9.5, 64 ± 5.3, 74.7 ± 12.9 cells/well, respectively) as well as the 
length (112.4 ± 9.1µm, 86.7 ± 9µm, 103.7 ± 1.1µm) of neurites in DPSC/retinal cell co-
cultures compared with DPSC/retinal cells co-cultured without inhibitors (Figure 3). 
Combining the Fc-TrK inhibitors further attenuated the number of βIII-tubulin+ retinal cells 
with neurites (38 ± 4.9 cells/well) as well as neurite length (53.9 ± 7.9µm) seen in the 
DPSC/retinal cell co-culture. Similar effects, although less exaggerated, were seen in the 
BMSC/retinal cell co-cultures. Accordingly, a statistically significant (p<0.05) reduced neurite 
length from 137.8 ± 2.3µm to 65.4 ± 2µm was only seen when the three neurotrophin 
inhibitors were combined in the BMSC/retinal cell co-culture, but not when each inhibitor was 
used in isolation. 
DPSC transplants preserved RNFL thickness for up to 14 days after optic 
nerve crush injury 
All transplanted animals and eyes survived the experiment with no observable adverse 
effects. 
Since the RNFL comprises RGC axons that pass over the surface of the retina towards the 
optic disk, RNFL thickness was used to measure post-axotomy RGC axonal atrophy and did 
not significantly (p<0.05) change in uninjured animals over time. In ONC animals, RNFL 
thickness was reduced significantly (p<0.05) from 49.3 ± 2.1µm to 30.2 ± 1.5µm at 7 dpl, 
21.4 ±1.6µm at 14 dpl and 17 ± 1.2µm at 21 dpl (Figure 4). Animals receiving dead 
DPSC/BMSC transplantations showed a similar thinning in RNFL thickness with no 
significant (p<0.05) difference from ONC alone. However, there was no significant (p<0.05) 
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RNFL thinning at 7 dpl in animals that were injected with living DPSC/BMSC (46.2 ± 1.4µm, 
46 ± 2.1µm, respectively) compared with intact animals at 7 dpl (45.7 ± 1.2µm) indicating a 
neuroprotective effect of the DPSC. At 14 dpl, RNFL thickness of the DPSC transplanted 
animal had decreased to 32.8 ± 0.7µm, which was significantly (p<0.05) lower than that in 
intact animals (45.4 ± 0.2µm) but still significantly (p<0.05) higher than in untreated animals 
(21.4 ± 1.6µm). This is in contrast to animals that received BMSC in which RNFL thickness 
decreased to 28.5 ± 1.6µm by 14dpl, which was not significantly (p>0.05) different from 
untreated animals. By 21 dpl, the RNFL in animals receiving either DPSC or BMSC (24 ± 
1.3µm, 22 ± 1.8µm, respectively) had reduced to a thickness not significantly (p>0.05) 
different to that seen in untreated animals at 21 dpl (17 ± 1.2µm). 
 
Figure 4: RNFL thickness after ONC. OCT images of retina from an uninjured rat (A) and a 
rat 21 days after ONC (B) are shown with red lines outlining the RNFL. OCT images were 
taken of the retinal section surrounding the optic nerve head, indicated by the green line (C). 
Images are representative of the 6 animals used in each treatment group (scale bar = 
200µm). The graph (D) depicts changes in RNFL thickness over time for uninjured optic 
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nerves (orange line), DPSC transplanted eyes (red line), BMSC transplanted eyes (blue 
line), dead DPSC transplanted eyes (dashed red line) and dead BMSC transplanted eyes 
(dashed blue line). Points marked with an * indicate significant difference from 
untreated/dead cell transplanted animals at p<0.05. 
 
Transplanted intravitreal DPSC survived in vivo for 21 days 
Viable DPSC were detected in the vitreous at 21dpl associated with elevated levels of BDNF 
and NT-3 in the retina at 21dpl compared to eyes transplanted with dead DPSC (Figure 5). 
Activated glial fibriliary acidic protein+ (GFAP) glia were also observed in eyes transplanted 
with DPSC but not with dead DPSC. Similar findings were observed with BMSC (data not 
shown). 
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Figure 5: DPSC survival and trophic effects 21 days after ONC/cell transplantation. 
Immunohistochemically stained 20µm thick parasagittal sections of retina and vitreous, 
stained for BDNF (A and B), NT-3 (C and D), GFAP (E and F) and Y chromosome (G) 21 
days after ONC and intravitreal transplantation of DPSC (A, C, E and G) or dead DPSC (B, 
D and F) with outer nuclear layer (ONL), inner nuclear layer (INL) and ganglion cell layer 
(GCL) labelled. A negative control with the primary antibodies omitted is included (F).  All 
images are representative of the 2 images per section, 4 sections per retina, 6 retinae from 6 
different animals per treatment group. DAPI was used as a nuclear counter stain (scale bars 
= 100µm). 
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Intravitreal DPSC transplants protected RGCs from death after ONC 
Intravitreal DPSC transplantation after ONC significantly increased (p<0.05) RGC survival at 
21 dpl (27.9 ± 2.0 RGCs/mm of retina) compared with animals receiving BMSC transplants 
(16.2 ± 1.3 RGCs/mm of retina), dead DPSC transplants (5.7 ± 0.6 RGCs/mm of retina) or 
ONC alone (6.9 ± 1.1 RGCs/mm of retina; Figure 6), as determined by Brn3a+ staining. 
Nonetheless, RGC survival after BMSC transplantation was also significantly (p<0.05) 
greater than in animals receiving dead BMSC transplants (8.4 ± 1.1 RGCs/mm of retina) or 
in untreated animals, demonstrating that BMSC exerted some neuroprotective effect for 
RGC, although at a lower level than did DPSC. 
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Figure 6: RGC survival 21 days after ONC/cell transplantation. Immunohistochemically 
stained 20µm thick parasagittal sections of retina, stained for βIII-tubulin (green) and Brn3a 
(red) in intact animals (A i) and 21 days after ONC (A ii) and intravitreal transplantation of 
dead BMSC (A iii), dead DPSC (A iv), living BMSC (A v) and living DPSC (A vi) with outer 
nuclear layer (ONL), inner nuclear layer (INL) and ganglion cell layer (GCL) labelled. All 
images are representative of the 2 images per section, 4 sections per retina, 6 retinae from 6 
different animals per treatment group. DAPI was used as a nuclear counter stain (scale bars 
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= 100µm). In panel B, the number of Brn3a+ RGCs, counted in a 1mm region of the GCL 21 
dpl is shown. Black lines indicate significant difference at p<0.05. 
 
Intravitreal DPSC transplants after ONC promoted RGC axon regeneration 
At distances of 100, 200, 400, 800 and 1200µm distal to the crush site, the number of 
regenerating GAP-43+  RGC axons was significantly (p<0.05) increased (284.7 ± 33.0, 221.0 
± 23.3, 214.5 ± 26.0, 181.9 ± 42.0, 115.9 ± 25.6 axons/nerve, respectively) after intravitreal 
transplantation of DPSC compared with BMSC (133.7 ± 21.1, 115.9 ± 25.0, 85.4 ± 19.8, 77.2 
± 10.4, 50.4 ± 10.3 axons/nerve, respectively), dead DPSC (68.7 ± 19.6, 54.4 ± 11.0, 42.7 ± 
8.6, 31.7 ± 15.3, 9.5 ± 4.9 axons/nerve, respectively) or untreated (78.1 ± 16.9, 48.6 ± 7.2, 
34.9 ± 6.0, 11.7 ± 3.7, 2.5 ± 1.5 axons/nerve, respectively; Figure 7) at 21 dpl. BMSC 
transplanted animals had significantly (p<0.05) greater numbers of regenerating RGC axons 
in the distal optic nerve compared with untreated animals at all distances and significantly 
(p<0.05) greater numbers of regenerating axons compared to animals receiving dead BMSC 
(59.7 ± 6.5, 45.5 ± 8.6, 46.7 ± 9.2, 40.4 ± 9.9, 18.2 ± 5.3 axons/nerve, respectively) at 
distances of 100 and 200µm distal to the crush site.  
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Figure 7: Regeneration of RGC axons in the optic nerve, 21 days after ONC/cell 
transplantation. Immunohistochemically stained 15µm thick longitudinal sections of optic 
nerves, stained for GAP-43 (green) and laminin (red) 21 days after ONC and DPSC (A i) or 
dead DPSC (A ii) transplantation with the crush site marked by an *. All images are 
representative of 3 sections per nerve, 6 nerves from 6 different animals per treatment group 
(scale bars = 100µm). The number of regenerating axons was measured at 100, 200, 400, 
800 and 1200µm from the ONC site at 21 dpl in untreated animals (purple bars), animals 
receiving intravitreal dead DPSC transplants (red dashed bars), dead BMSC (blue dashed 
bars), living BMSC (blue bars) and living DPSC (red bars), black lines indicate significant 
difference at p<0.05. Note GAP-43+ axons outside basal lamina of optic nerve = peripheral 
innervation of the tissue. 
 
Discussion 
This study provides evidence that DPSC, through secretion of neurotrophins, significantly 
increase both survival and neuritogenesis of primary adult rat βIII-tubulin+ retinal cells in an 
in vitro co-culture assay. Furthermore, when transplanted into the vitreous body of adult rats 
after ONC, DPSC significantly promote Brn-3a+ RGC survival and axon regeneration. 
Noteworthy, the neuroprotective and pro-regenerative effects of DPSC seen in these in vitro 
and in vivo models was greater than that observed with BMSC, which can be related to their 
enhanced neurotrophic profile as determined by ELISA and suggests that DPSC have a 
greater potential to repair CNS/retinal injury.  
Our findings are consistent with a recent study that demonstrated greater positive effects of 
locally transplanted DPSC on locomotory recovery from SCI than did BMSC transplants21. 
Moreover, the improvement in locomotory function after cell transplantation into a SCI site 
occurred in the absence of local neuronal differentiation, suggesting that the transplanted 
cells acted indirectly, creating a more supportive trophic environment for endogenous axonal 
sprouting/growth.  
Our finding that DPSC enhanced βIII-tubulin+ retinal cell survival and neurite outgrowth in a 
co-culture model can be attributed to the release of soluble factors, since the two 
populations of cells were separated by a porous membrane. Moreover, the use of specific 
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Fc-TrK inhibitors enabled us to identify DPSC-derived NGF, BDNF and NT-3 as important 
NTF responsible for this neuroprotective and neuritogenic effect. Use of individual Fc-TrK 
inhibitors as opposed to combined demonstrated that NGF, BDNF and NT-3 each had 
equally important neuroprotective and neuritogenic effects. The ELISA measurements 
confirmed the secretion of these factors by the DPSC, corroborating previous work showing 
that DPSC express multiple NTF mRNA, including neurotrophins21, 31-33. Interestingly, BMSC 
exhibited a less potent neurotrophic effect on cultured βIII-tubulin+ retinal cells than DPSC; 
and this novel observation can be related to their reduced neurotrophin profile. Of note, 
K252a, a non-specific blocker of TrK receptors as well as other protein kinases, further 
reduced the neuritogenic effect of DPSC/BMSC compared to Fc-Trk blockade. These 
findings suggest that other TrK-independent growth factors may also mediate the 
neurotrophic effects of DPSC/BMSC. Indeed, DPSC express other trophic factors such as 
GDNF30. By contrast, neuroprotection was similarly reduced after both K252a and TrK 
blockade, suggesting that the stem cell-derived neurotrophins NGF, BDNF and NT-3 were 
the primary RGC neuroprotective agents. 
Axotomy interrupts the supply of retrogradely transported neuroprotective NTF and, in many 
cases, the neuron subsequently dies, with RGCs being exquisitely sensitive to such 
adversities10, 41. Neurotrophins also play an important role in growth cone 
formation/elongation and are relatively abundant in the peripheral nervous system compared 
with the CNS, possibly explaining the disparity between the axon regenerative response of 
the two sites. DPSC/BMSC provide an alternative source of NTF for axotomised RGCs, 
protecting them from death and promoting RGC axogenesis. 
After ONC, RGCs begin dying from 7 dpl42 with 80-90% dead by two to three weeks6, 10, 41, 
thus making this a suitable in vivo model to assess DPSC-mediated effects on RGC survival. 
We utilised two methods of assessing RGC number in our in vivo model, firstly OCT was 
used to measure the thickness of the RNFL, which is comprised of the axons of the RGCs. 
These are lost concomitantly with RGC death and thus provide a means of monitoring 
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axonal atrophy in real time. Secondly, Brn3a+ RGCs in the ganglion cell layer of retinal 
sections were counted at 21 dpl, a method that excludes amacrine cells and astrocytes from 
the counts39. 
OCT recordings showed that in intact animals, RNFL thickness remained constant overtime, 
whereas after ONC, RNFL thickness was progressively and significantly reduced. DPSC or 
BMSC transplantation resulted in 100% RGC neuroprotection for up to 7 dpl but by 14 dpl, 
significant neuroprotection was only seen in animals treated with DPSC. By 21 dpl, RNFL 
thickness was decreased in all ONC groups suggesting that cell-mediated neuroprotection 
was failing. Thus, the OCT data suggest that RGC death was significantly delayed but not 
entirely averted. Reasons for the transient neuroprotective effect of the transplanted cells 
may be ligand-mediated down-regulation of the TrK receptors14, 15 and/or gradual loss of the 
grafted cells with concomitant loss of neurotrophin-mediated protection of RGCs.  However, 
Y chromosome+ immunohistochemical staining indicated that DPSC persisted in the vitreous 
of rats 21 days after transplantation. Further studies are required to analyse in detail the 
survival and fate of the transplanted stem cells in the vitreous of the eye. 
 
Corroborating the OCT results, significantly more Brn3a+ RGCs were present in the retinae 
of animals that received intravitreal transplants of either BMSC or DPSC compared with 
controls (i.e. untreated animals or those receiving dead BMSC/DPSC). This corroborates the 
RNFL thickness data suggesting that OCT is a valid method for monitoring RGC survival, 
although immunocytochemical analysis proves a more direct as well as a more sensitive 
approach. RGC survival was more pronounced in animals receiving DPSC compared with 
those receiving BMSC transplants, correlating with our in vitro co-culture results as well as 
ELISA data, highlighting higher titres of neurotrophins produced by the DPSC. These 
findings are also consistent with well documented data demonstrating therapeutic short term 
effects of injected recombinant neurotrophins10, 11.  
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This study provides new evidence that DPSC are neuroprotective for RGCs and is supported 
by the reports of reduced numbers of apoptotic neurons seen after SCI when DPSC are 
transplanted into the lesion site21. Three other studies have shown significant RGC survival 
after intravitreal cell transplantation. The first two used BMSC in an animal model of 
glaucoma24 and optic nerve transection23 and the other study used intravitreally transplanted 
fibroblasts genetically modified to express NTF in the same ONC rat model used in this 
study16. All these studies showed significant, though short term, RGC survival and attribute 
this effect to the release of NTF by the transplanted cells. In particular, it was reported that 
BMSC transplantation resulted in RGC survival of 66% compared with 46% in untreated 
animals at 8 dpl23. This protection appears substantially less than that achieved in the 
current study (complete protection after 7 days) as assessed by OCT but can be explained 
by the fact that the authors23 transplanted BMSC 3 days before the ONC, meaning that the 
RGC counts were done 11 days after BMSC transplantation. It is likely that the efficacy of 
the transplanted cells diminished significantly by 11 days and that the neuroprotective effect 
was equally diminished. This also concurs with our findings that the neuroprotective effects 
of the transplanted cells became less pronounced over time. 
The promising neurite outgrowth stimulated by the DPSC seen in the in vitro co-culture 
experiments were supported by the GAP-43+ RGC axon regenerative response seen in the 
in vivo ONC experiment. Accordingly, intravitreal transplantation of DPSC increased the 
number of GAP-43+ axons in the proximal stump with many crossing the lesion site and 
regenerating into the distal optic nerve. As well as more pronounced axon regeneration 
through the lesion site, the distal nerve stump contained significantly more GAP-43+ axons 
that persisted for long distances through the putative axon growth inhibitory environment of 
the distal optic nerve. Finally, less laminin+ scar tissue was seen at crush sites traversed by 
regenerating axons, which is a well-documented correlation6, 43. Indeed, in all the 
DPSC/BMSC transplanted animals with regenerating RGC axons, no scar tissue was 
present at the lesion site. This phenomenon has been attributed to secretion of 
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metalloproteinases and plasminogen by the regenerating axons that block meningeal 
fibroblast migration into the wound and degrade scar tissue6, 44. Thus, the lack of scar tissue 
is an additional indication of DPSC-induced RGC axon regeneration.  
This study demonstrates the potential therapeutic benefit of DPSC to stimulate the growth of 
axons along the long non-permissive distances required to restore neural function. Our 
finding also suggest that the regenerating axons were disinhibited by the DPSC-derived 
neurotrophins, presumably through regulated intramembrane proteolysis of inhibitory 
receptors and dissolution of chondroitin sulphate proteoglycans45, and corroborates a 
previous ONC study in which a significant number of RGC axons regenerated into the distal 
optic nerve after intravitreal transplantation of fibroblasts genetically modified to express 
FGF-2, BDNF and NT-316. Our results also support the recent work that concluded that the 
transplantation of DPSC promoted axonal regeneration across a SCI lesion site21. 
It cannot be ruled out and is not mutually exclusive in the aforementioned explanation that 
the neuroprotective and neuritogenic/axogenic effects seen in this study are attributable to 
an indirect interaction between the stem cell-derived neurotrophins and the βIII-tubulin+ 
retinal cells mediated by GFAP+ retinal glia, which also secrete NTF. In addition, 
inflammation triggers the release of CNTF from GFAP+ retinal glia resulting in RGC 
neuroprotection and axogenesis46, 47. In this study, we show glial cell activation 21 days after 
stem cell transplantation, which suggests that glia have a role in the induction of stem cell-
directed neuroprotection/axogenesis although increased neurotrophin titres in eyes at 21 dpl 
may be stem cell-derived, glial-derived or a combination of both. Thus, it is possible that up-
regulation of glial NTF production contributed to the neuroprotective and axogenic effects 
seen after stem cell transplantation. 
We report here for the first time that intravitreal BMSC promoted a small but significant 
regeneration of RGC axons, even at 1200µm distal to the crush site. Nonetheless, DPSC 
promoted significantly greater regeneration of RGC axons than did BMSC, reflecting their 
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elevated neurotrophin secretion profile and underlining the potential benefit of DPSC above 
other mesenchymal cell sources.  
An important future consideration would be to develop a safe and more sustained delivery 
mechanism for the cells. In the present study cells were injected as a suspension which 
carries with it certain risks, such as migration of the cells into endogenous tissue and their 
uncontrolled proliferation. Encapsulation of cells in biologically compatible materials for 
transplantation into the vitreous has already been shown with a retinal cell line that had been 
genetically modified to release CNTF in both animal models48 and patients49. Not only did 
the encapsulated cells survive for 6 months49 but they were also retrievable. Further studies 
are ongoing in our laboratory to develop a similar delivery mechanism for adult human 
DPSC. 
Conclusions 
We demonstrate here for the first time that DPSC secrete multiple neurotrophins which were 
at least in part responsible for promoting axotomised RGC neuroprotection and 
neuritogenesis/axogenesis, both in vitro and in vivo. DPSC were more effective than BMSC, 
which is likely due to the higher titres of neurotrophin secretion by the DPSC. DPSC may be 
a promising alternative for a CNS regenerative cell therapy. 
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ABSTRACT 
We have investigated and compared the neurotrophic activity of human dental pulp stem 
cells (hDPSC), human bone marrow-derived mesenchymal stem cells (hBMSC) and human 
adipose-derived stem cells (hADSC) on axotomised adult rat retinal ganglion cells (RGC) in 
vitro in order to evaluate their therapeutic potential for neurodegenerative conditions of RGC.  
Using the transwell system, RGC survival and length/number of neurites were quantified in 
coculture with stem cells in the presence or absence of specific Fc-receptor inhibitors to 
determine the role of NGF, BDNF, NT-3, VEGF, GDNF, PDGF-AA and PDGF-AB/BB in 
stem cell-mediated RGC neuroprotection and neuritogenesis. Conditioned media, collected 
from cultured hDPSC/hBMSC/hAMSC, were assayed for the secreted growth factors 
detailed above using ELISA. PCR array determined the hDPSC, hBMSC and hAMSC 
expression of genes encoding 84 growth factors and receptors. 
The results demonstrated that hDPSC promoted significantly more neuroprotection and 
neuritogenesis of axotomised RGC than either hBMSC or hAMSC, an effect that was 
neutralized after the addition of specific Fc-receptor inhibitors. hDPSC secreted greater 
levels of various growth factors including NGF, BDNF and VEGF compared with 
hBMSC/hAMSC. The PCR array confirmed these findings and identified VGF as a novel 
potentially therapeutic hDPSC-derived neurotrophic factor (NTF) with significant RGC 
neuroprotective properties after coculture with axotomised RGC. 
In conclusion, hDPSC promoted significant multi-factorial paracrine-mediated RGC survival 
and neurite outgrowth and may be considered a potent and advantageous cell therapy for 
retinal nerve repair. 
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INTRODUCTION 
The axons of retinal ganglion cells (RGC) transmit action potentials along the optic nerve to 
the superior colliculus (SC) and lateral geniculate nucleus (LGN) that are relayed onwards to 
the visual cortex. Axotomised RGC die[1,2] so that blindness ensues after traumatic (crush 
or transection)[3] optic nerve injury. RGC loss is caused by a failure in the supply of 
neurotrophic factors (NTF; including neurotrophins), retrogradely transported from the 
SC/LGN neurons, that act as survival signals, ensuring the functional integrity of RGC 
connections[4-6].  
As well as protecting RGC from death, NTF have the potential to promote the regeneration 
of transected axons and establish re-connection with their targets. The paucity of NTF in the 
central nervous system (CNS) is one explanation for the lack of axon regeneration compared 
to the peripheral nervous system (PNS)[2,7] in which successful and functional axon 
regeneration occurs, largely promoted by Schwann cell-derived NTF[8]. Attempts to promote 
long distance axon regeneration by the transplantation of peripheral nerve grafts into the 
CNS have met with some success[9]. For example, grafting a peripheral nerve into the 
vitreous body after optic nerve crush[8] promotes more RGC axon regeneration in the 
transected optic nerve than occurs after the removal of Schwann cells before 
transplantation, suggesting that axotomised RGC regenerate their axons when provided with 
a constant supply of NTF. However, single NTF supplementation[7], or single dose 
treatments of NTF such as BDNF[10,11], have proven unsuccessful and sustained delivery 
of multiple NTF to RGC over extended periods of time is difficult to achieve.  
The vitreous is a relatively accessible immunoprivileged transplantation site[12] that lies 
directly adjacent to the RGC layer of the retina, allowing diffusion or transport of NTF across 
the inner limiting membrane to the RGC. Previously, we used intravitreally transplanted 
genetically modified fibroblasts expressing FGF-2, BDNF and NT-3 to promote RGC survival 
and axon regeneration after optic nerve crush[7]. Since the translational potential of 
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genetically modified cells is limited, mesenchymal stem cells (MSC), which secrete a large 
array of NTF, have gained credence as a potential cell therapy for diseased and injured CNS 
neurons. Human bone marrow-derived mesenchymal stem cells (hBMSC) protect RGC from 
death in both optic nerve crush[13] and glaucoma experimental models[14-16] through the 
production of NTF (e.g. platelet-derived growth factor (PDGF)[15]), without differentiation of 
hBMSC into replacement RGC/RGC-like cells. 
We recently demonstrated that rat dental pulp stem cells (DPSC) protected adult rat RGC 
from death in an optic nerve crush model[17,18]. This effect was significantly greater than 
that achieved by rat BMSC and mediated through nerve growth factor (NGF), brain-derived 
neurotrophic factor (BDNF) and neurotrophin 3 (NT-3) via, TrKA, B and C receptor 
signalling. Our findings were consistent with previous studies showing significant 
expression[19,20] and secretion of NGF, BDNF and NT-3 by hDPSC[21]. The 
neuroprotective and axogenic properties of DPSC[17,18] and BMSC[14,15,22] can also be 
found in other MSC types, in particular adipose-derived mesenchymal stem cells (AMSC) 
that also secrete multiple NTF[22,23] and promote functional recovery after CNS trauma 
including spinal cord injury[22,24], stroke[25] and light induced photoreceptor 
damage[26,27]. However, AMSC have not been tested in a model of RGC death. 
Comparative analyses of different human MSC is still lacking although important for the 
determination of the most efficacious paracrine-mediated therapy for the injured retina. Thus, 
the aim of this study was to evaluate and compare the neuroprotective and neuritogenic 
effects of hDPSC, hBMSC and hAMSC and to define the stem cell NTF secretome using 
ELISA and PCR microarray analysis.  
MATERIALS AND METHODS 
All reagents were purchased from Sigma (Poole, UK) unless otherwise specified. 
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DPSC/BMSC/AMSC cultures 
hDPSC were purchased from AllCell LLC (Berkeley, CA) and both hBMSC and hAMSC from 
Lonza (Slough, UK), and each represented pooled samples from 3 donors. The 
CD29+/CD44+/CD73+/CD90+/CD45- (confirmed by supplier) stem cells were seeded into 
T25/T75 flasks (Corning, Amsterdam, NL) in both a total volume of 5ml/15ml DMEM 
containing 1% penicillin/streptomycin and 10% foetal bovine serum (FBS; Hyclone 
Laboratories, Logan, UT) and at a density of 1x106 cells/2x106 cells, respectively. Cultures 
were maintained at 37°C in 5% CO2, the supplemented medium was changed every 3d and 
the cells were passaged when 80% confluent using 0.05% trypsin/EDTA to lift them from 
their surface attachment. 
Animals 
Nine adult male Sprague-Dawley rats weighing 170-200g (Charles River, Kent, UK) were 
housed under Home Office guidelines in conditions of 21°C and 55% humidity under a 12h 
light and dark cycle, given food/water ad libitum and were under constant supervision from 
trained staff. Animals were killed by “Schedule 1 Methods” i.e. rising concentrations of CO2 
before extraction of retinae. Ethical approval by the University of Birmingham ethical review 
Sub-Committee for this study was not required due to the in vitro nature of the experiment. 
Retinal cell coculture 
Cell culture 24-well plates (BD Biosciences, Oxford, UK) were pre-coated with 100µg/ml 
poly-D-lysine for 60min and then with 20µg/ml laminin for 30min. After culling and ocular 
dissection, the retinae of nine male Sprague-Dawley were minced in 1.25ml of papain 
(20U/ml; Worthington Biochem, Lakewood, NJ; as per manufacturer’s instructions) 
containing 50µg/ml of DNase I (62.5µl; Worthington Biochem) and incubated for 90min at 
37°C. The retinal cell suspension was centrifuged at 300xg for 5min and the pellet 
resuspended in 1.575ml of Earle’s balanced salt solution (Worthington Biochem) containing 
1.1 mg/ml of reconstituted albumin ovomucoid inhibitor (150µl; Worthington Biochem) and 
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56µg/ml of DNase I (75µl). After adding to the top of 2.5ml of albumin ovomucoid inhibitor 
(10mg/ml) to form a discontinuous density gradient, the retinal cell suspension was 
centrifuged at 70xg for 6min and the cell pellet resuspended in 1ml of supplemented 
Neurobasal-A (25ml Neurobasal-A (Life Technologies, Gibco, Paisley, UK), 1X concentration 
of B27 supplement (Life Technologies, Invitrogen, Paisley, UK), 0.5mM of L-glutamine 
(62.5µl; Invitrogen) and 50µg/ml of gentamycin (125µl; Invitrogen)) and seeded at a density 
of 125,000 cells/800µl/well in a 24 well plate. Previous immunocytochemical analysis of 
these cultures in our lab demonstrates that 60% of these retinal cells are neurons 
(neurofilament+/βIII-tubulin+), of which 10% are Thy1+ RGC[28]. 
hDPSC, hBMSC and hAMSC were used at passage 2-4 and plated at a density of 50,000 
cells/200µl onto a 0.4µm porous cell culture insert (Millipore, Watford, UK) that was placed 
into each of the 24 wells containing retinal cells to give a total volume of 1ml of medium/well. 
Particular wells containing retinal cell cultures were treated either singly or in combination 
with 5µg/ml Fc-TrKA, Fc-TrKB and/or Fc-TrKC (R&D Systems, Abingdon, UK) as well as Fc-
VEGFr, Fc-GDNFr, Fc-PDGFAr and Fc-PDGFBr fusion protein inhibitors[29] (R&D Systems) 
which are highly specific inhibitors for the corresponding cognate neurotrophic factor 
receptors (NTFR). A combination of recombinant human NGF, BDNF and NT-3 was also 
added to some retinal cell cultures at 60ng/ml as a positive control. Particular wells 
containing retinal cells were treated with 0.1µm, 1µm and 10µm of VGF (R&D Systems) 
instead of hDPSC/hBMSC/hAMSC. 
Cocultures were incubated for 3d at 37°C before immunocytochemical staining of RGC with 
βIII-tubulin. For this study, large spherical βIII-tubulin+ retinal cells[30] cultured after neuronal 
isolation from retinae, are referred to as RGC. βIII-tubulin is a reliable and relatively specific 
marker for RGC[30], although cross reactivity with amacrine cells has been suggested[31]. 
However, it should be emphasised, that the isolation procedure and growth medium used 
preferentially selects and yields populations of neuronal cells, we are confident that our 
findings accurately reflect RGC numbers. All experiments were repeated on 3 separate 
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occasions. Each of the treatment groups in each of the 3 experimental runs comprised 3 
replicate wells containing retinal cells harvested from one animal. 
Immunocytochemistry 
Retinal cells in 24 well plates (BD Biosciences) were fixed in 4% paraformaldehyde (PFA) in 
phosphate-buffered saline (PBS) for 10min, washed for 3 X 10min of PBS, blocked in 
blocking solution (0.5% bovine serum albumin (g/ml), 0.3% Tween-20, 15% normal goat 
serum (Vector Laboratories, Peterborough, UK) in PBS) for 20min and incubated with 
primary antibody (anti-rat βIII-tubulin, raised in mouse, #T8660 diluted at 1:500 in antibody 
diluting buffer (ADB; 0.5% bovine serum albumin, 0.3% Tween-20 in PBS) for 1h at room 
temperature. Cells were then washed for 3 X 10min in PBS, incubated with the secondary 
antibody (anti-mouse IgG Fluor 488, raised in goat, 1:400, #A-11001; Life Technologies, 
Molecular Probes, Paisley, UK) diluted in ADB for 1h at room temperature, washed for 3 X 
10min in PBS, mounted in Vectorshield mounting medium containing DAPI (Vector 
Laboratories) and stored at 4°C. 
Microscopy and analysis 
For immunocytochemistry, all βIII-tubulin+ RGC, with or without neurites, were counted in 
each well of the 24 well plates, recording the total number of RGC and the number of RGC 
with neurites. Neurite outgrowth was measured in images taken at 20X magnification using 
an Axiocam HRc camera (Carl Zeiss Ltd, Hertfordshire, UK). Each well was divided into 9 
equal sectors and the length of the longest neurite of each RGC in each sector was 
measured using Axiovision software (Carl Zeiss Ltd). Fluorescently stained cells were 
analysed by an operator blinded to treatment groups, using a Zeiss Axiovert fluorescent 
microscope (Carl Zeiss Ltd). 
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NTF ELISA 
To quantify the growth factors and NTF produced by hDPSC, hBMSC and hAMSC, 
conditioned medium was collected from cultures at passage 2 and 5 after 48h in culture and 
assayed using a duoset ELISA kit for human NGF, BDNF and NT-3, VEGF, GDNF, platelet-
derived growth factor (PDGF-AA) and PDGF-AB/BB according to the manufacturer’s 
instructions (R&D Systems). Briefly, a standard curve was constructed using NTF standards 
and test samples of conditioned medium at increasing dilutions, run in duplicate with NTF 
concentrations extrapolated from the standard curve. Values were normalized to the number 
of cells in the flask (manually counted via haemocytometer) and the volume of medium, and 
corrected for analyte found in the medium/serum. 
Human NTF and NTFR PCR array 
The expression of 84 NTF and NTFR genes by hDPSC, hBMSC and hAMSC (passage 2) 
was assayed using quantitative RT-PCR profiler arrays (PAMM-031) by a commercially run 
service (Sabiosciences, Qiagen, Hilden, Germany). Housekeeping genes (b2m and hprt1) 
were used to normalize the data and the –ΔCt compared between cell types and expressed as 
+ or - fold changes. Samples contained one million cells and were run in triplicate. 
Statistics 
All statistical tests were performed using SPSS 17.0 (IBM SPSS, Inc., Chicago, IL) and data 
presented as mean ± standard error of the mean (SEM). The Shapiro-Wilkes test was used 
to ensure all data were normally distributed before parametric testing using a one-way 
analysis of variance (ANOVA) with a Tukey post-hoc test. Statistical differences were 
considered significant at p values <0.05. For the qRT-PCR, data were compared by a 
Student’s t test and statistical significance set at p<0.001. 
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RESULTS 
hDPSC promoted significantly greater paracrine-mediated neuroprotection and 
neuritogenesis than hBMSC/hAMSC 
hDPSC, hBMSC and hAMSC all promoted a significant increase (p<0.05) in the survival of 
cocultured RGC (282.7 ± 17.1 cells/well; 219 ± 28.4 cells/well; 200.0 ± 10.2 cells/well; 
respectively) compared with retinal cells cultured alone (100.7 ± 9.5 cells/well); hDPSC, 
hBMSC and hAMSC neuroprotection was similar to the level obtained after retinal cell 
culture with recombinant NGF/BDNF/NT-3 (239.7 ± 15.4 cells/well; Figs. 1, 2.). The increase 
in survival of RGC in hDPSC-treated retinal cultures was significantly greater (p<0.05) than 
that achieved in cocultures with hAMSC (p<0.05) but not significantly greater than that seen 
in cocultures with hBMSC. 
Coculture of retinal cells with hDPSC, hBMSC and hAMSC significantly increased (p<0.05) 
the percentage of surviving RGC bearing tubulin+ neurites (64.8 ± 4.0%, 51.1 ± 2.1%, 42.2 ± 
4.3%, respectively), as well as the length of neurites (236.7µm ± 27.6µm, 150.7µm ± 
24.1µm, 101.1µm ± 12.1µm, respectively) compared with retinal cells cultured alone (18.2 ± 
4.6%; 32.8µm ± 1.4µm; Fig. 1, 2.). Coculture with hDPSC promoted a significant increase 
(p<0.05) in the number of neurite-bearing RGC as well as neurite length when compared 
with cocultures with hBMSC and hAMSC, or with retinal cultures exposed to recombinant 
NGF, BDNF and NT-3. These data confirm that hDPSC, hBMSC and hAMSC have 
paracrine-mediated neuroprotective and neuritogenic properties, with hDPSC promoting the 
most significant effects. 
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Figure 1: Effects of hDPSC, hBMSC and hAMSC on axotomised RGC in culture. The 
number of RGC (A), percentage of surviving RGC bearing neurites (B) and the length of the 
longest RGC neurite (C) in both untreated retinal cultures and after coculture with hDPSC, 
hBMSC, hAMSC, with or without added exogenous neurotrophins. Black lines indicate 
significant difference at P < 0.05. The effects of Fc-TrKA, -B, -C, Fc-GDNFr, Fc-VEGFr, Fc-
PDGFAr and Fc-PDGFBr inhibitors on RGC survival (A) and neuritogenesis (B, C) in 
hDPSC, hBMSC and hAMSC cocultures are also shown (values marked with an asterisk 
indicate significant difference from uninhibited cultures at P < 0.05). 
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Figure 2: Immunocytochemical staining of RGC after retinal coculture with hDPSC, hBMSC 
and hAMSC in transwell inserts. In vitro RGC cultured either alone (A), with exogenous 
neurotrophins (B), with hAMSC (with or without TrK inhibitors (C, D, respectively)), with 
hBMSC (with or without TrK inhibitors (E, F, respectively)) or with hDPSC (with or without 
TrK inhibitors (G, H, respectively). All images are representative of the entire culture, nine 
separate culture wells/treatment, with every three wells using a different animal (scale bars: 
50µm), cell nuclei were stained with DAPI. 
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NTFR Fc-receptor blockers for multiple NTFR attenuated the neuroprotective and 
neuritogenic effect of hDPSC/hBMSC/hAMSC 
The NTFR blockers Fc-TrKA, Fc-TrKB, Fc-TrKC, Fc-TrKA/B/C, Fc-GDNFr, Fc-VEGFr, Fc-
PDGFAr and Fc-PDGFBr significantly attenuated hDPSC mediated neuroprotection and/or 
neuritogenesis of cocultured RGC (Table. 1; Fig. 1, 2.) compared to uninhibited 
hDPSC/retinal cell cocultures. Fc-TrKA, Fc-TrKB, Fc-TrKC, Fc-TrKA/B/C, Fc-PDGFAr and 
Fc-PDGFBr significantly attenuated hBMSC mediated neuroprotection and/or neuritogenesis 
of cocultured RGC compared to uninhibited hBMSC/retinal cell cocultures. Fc-TrKA/B/C, Fc-
PDGFAr and Fc-PDGFBr significantly attenuated hAMSC mediated neuroprotection and/or 
neuritogenesis of cocultured RGC compared to uninhibited hAMSC/retinal cell cocultures. 
These data demonstrate that the neuroprotective and neuritogenic effects afforded by each 
of the stem cell types are mediated through a variety of different NTF. 
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Treatment  
Without 
inhibition 
Fc-
TrKA 
Fc-
TrKB 
Fc-
TrKC 
Fc-
TrKA/B/C 
Fc-
GDNFr 
Fc-
VEGFr 
Fc-
PDGFAr 
Fc-
PDGFBr 
hDPSC 
RGC/well 
282.7 ± 
17.1 
153.0 
± 
12.1 
129.3 
± 8.5 
163.3 
± 9.4 
118.3 ± 
4.3 
143.3 
± 6.6 
164.7 
± 10.7 
136.3 ± 
27.1 
106.0 ± 
11.3 
% 
surviving 
RGC 
with 
neurites 
64.8 ± 
4.0 
20.0 
± 3.2 
37.1 
± 2.4 
35.9 
± 5.8 
19.2 ± 
1.3 
32.3 ± 
3.4 
44.5 ± 
1.4 
57.0 ± 
12.1 
60.1 ± 
9.7 
Length of 
longest 
neurite 
(µm) 
236.7 ± 
27.6 
86.4 
± 7.0 
121.6 
± 
16.1 
158.2 
± 5.1 
60.6 ± 
14.8 
148.9 
± 22.2 
130.8 
± 15.4 
229.5 ± 
18.4 
241.6 ± 
17.6 
hBMSC 
RGC/well 
219 ± 
28.4 
143.0 
± 
11.4 
128.7 
± 
13.6 
124.0 
± 
15.4 
112.7 ± 
11.0 
165.3 
± 11.9 
171.0 
± 11.6 
123.7 ± 
8.0 
87.7 ± 
16.1 
% 
surviving 
RGC 
with 
neurites 
51.1 ± 
2.1 
21.9 
± 2.5 
30.1 
± 5.7 
57.3 
± 7.0 
21.4 ± 
4.1 
40.5 ± 
3.0 
44.83 
± 8.0 
39.9 ± 
1.4 
50.6 ± 
9.0 
Length of 
longest 
neurite 
(µm) 
150.7 ± 
24.1 
72.0 
± 7.8 
119.9 
± 
15.3 
131.1 
± 
17.6 
47.9 ± 
4.2 
156.7 
± 14.2 
135.0 
± 8.9 
97.4 ± 
18.2 
91.3 ± 
15.0 
hAMSC 
RGC/well 
200.0 ± 
10.2 
130.0 
± 
13.1 
171.3 
± 
10.4 
160.0 
± 2.6 
110.3 ± 
1.2 
165.3 
± 11.9 
171.0 
± 11.6 
116.3 ± 
15.9 
115.7 ± 
14.5 
% 
surviving 
RGC 
with 
neurites 
42.2 ± 
4.3 
23.5 
± 4.8 
36.6 
± 6.0 
29.0 
± 3.0 
23.7 ± 
3.5 
44.6 ± 
4.7 
36.6 ± 
4.7 
41.3 ± 
5.3 
41.6 ± 
2.4 
Length of 
longest 
neurite 
(µm) 
101.1 ± 
12.1 
77.1 
± 4.3 
80.8 
± 
13.1 
83.6 
± 
14.2 
49.1 ± 
3.6 
156.7 
± 14.2 
135.0 
± 8.9 
97.6 ± 
10.5 
125 ± 
19.5 
Table 1: The number of surviving RGC (cells/well), percentage of surviving RGC growing 
neurites (%) and the length of the longest neurite (µm) after coculture of RGC with hDPSC, 
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hBMSC or hAMSC and inhibition with Fc-TrKA, Fc-TrKB, Fc-TrKC, Fc-TrKA/B/C, Fc-GDNFr, 
Fc-VEGFr, Fc-PDGFAr and Fc-PDGFBr; values significantly (p<0.05) different from 
coculture without inhibition are given in bold (Mean +/- SEM; n = 3).  
hDPSC, hBMSC and hAMSC have distinct NTF expression profiles 
The PCR array detected 84 NTF and NTFR genes differentially expressed by hDPSC, 
hBMSC and hAMSC. For example, hDPSC express ≥4 fold higher cd40, crhbp, grpr, il1r1, 
ntrk1, ptger2 and vgf than hBMSC and ≥4 fold higher bdnf, gdnf, grpr, nt-3, ptger2, tacr1 and 
vgf than hAMSC (Fig. 3.). hDPSC express ≥4 fold lower cckar, fgf9, gfra1, hspb1, il1b, il6, 
ngfr, ntrk2, ntsr1, stat1, stat4 and tgfa than hBMSC and ≥4 fold lower adcyap1r1, bcl2, cxcr4, 
fgf9, gfra1, il1b, il6, ntrk2, ppyr1, stat1, tgfa than hAMSC. Significant differences (p<0.001) 
are highlighted in the graph (Fig. 3). These data confirm that, despite hDPSC, hBMSC and 
hAMSC all being designated as mesenchymal stem cells, the NTF secretome is distinct 
between each stem cell phenotype. 
 
Figure 3: Expression of NTF and NTFR genes by hDPSC, hBMSC and hAMSC. RT-PCR 
array analysis of 84 genes encoding NTF and NTFR expressed by hDPSC, displayed as fold 
regulation in comparison to either hBMSC (black bars) or hAMSC (grey bars). The horizontal 
dotted lines represent fold-changes of ±1 (no difference). Significant differences between 
hDPSC and hBMSC (*) and hDPSC and hAMSC (†) at p < 0.05 are labelled on the x axis. 
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hDPSC secrete multiple NTF at higher levels than hBMSC/hAMSC 
The levels of secretion by hDPSC, hBMSC and hAMSC of NGF, BDNF, NT-3, VEGF, 
GDNF, PDGF-AA, PDGF-AB/BB and CNTF, at passage 2 and 5, are detailed in Table 2, 
and presented as pg/100,000 cells/48h. CNTF and PDGF-AB/BB were undetectable in 
hDPSC/hBMSC/hAMSC conditioned media, while BDNF and NT-3 were undetectable in 
hAMSC conditioned medium. The hDPSC secreted significantly greater (p<0.05) titres of 
NGF, BDNF and VEGF than hBMSC/hAMSC (Table. 2; Fig. 4.). These data confirm that the 
hBMSC, hAMSC, and in particular, hDPSC secrete a variety of different NTF. 
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Figure 4: NGF, BDNF, NT-3, CNTF, VEGF, GDNF, PDGF-AA and PDGF-AB/BB titres by 
ELISA in hDPSC, hBMSC and hAMSC. hDPSC-, hBMSC- and hAMSC-conditioned media 
(passage 2 and 5) collected after 48h of cell culture (n = 3; asterisks indicate significant 
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differences from all other samples/black lines indicate significant difference between specific 
samples at p < 0.05). CNTF and PDGF-AB/BB were undetectable in all samples. 
 
  NGF BDNF NT-3 VEGF GDNF 
PDGF-
AA 
PDGF-
AB/BB 
CNTF 
hDPSC 
Passage 
2 
428.0 ± 
149.0 
141.9 ± 
14.4 
639.8 ± 
134.9 
314.7 ± 
53.9 
113.2 ± 
13.1 
216.0 ± 
19.0 
0 0 
Passage 
5 
331.2 ± 
94.8 
118.3 ± 
9.2 
385.3 ± 
32.6 
287.3 ± 
98.4 
151.7 ± 
51.6 
178.9 ± 
11.0 
0 0 
hBMSC 
Passage 
2 
20.4 ± 
9.5 
44.1 ± 
4.8 
487.4 ± 
65.4 
314.7 ± 
53.9 
161.2 ± 
5.2 
149.2 ± 
7.9 
0 0 
Passage 
5 
37.7 ± 
20.7 
76.0 ± 
12.6 
316.2 ± 
58.3 
251.2 ± 
54.9 
244.3 ± 
94.2 
126.8 ± 
23.2 
0 0 
hAMSC 
Passage 
2 
46.1 ± 
17.5 
0 0 
167.6 ± 
57.2 
35.5 ± 
20.2 
210.3 ± 
87.1 
0 0 
Passage 
5 
33.2 ± 
14.0 
0 0 
66.7 ± 
10.5 
23.6 ± 
10.0 
93.9 ± 
29.8 
0 0 
Table 2: The titre of secreted NGF, BDNF, NT-3, VEGF, GDNF, PDGF-AA, PDGF-AB/BB 
and CNTF in conditioned media from hDPSC, hBMSC and hAMSC at passage 2 and 5, as 
determined by ELISA. Data are presented as pg/100,000 cells/48h (Mean +/- SEM; n=3). 
VGF was neuroprotective for RGC 
The differentially and significantly greater transcription of vgf in hDPSC compared to 
hBMSC/hAMSC (Fig. 3.) led to investigation of the neuroprotective and/or proregenerative 
properties of VGF. VGF promoted a significant increase (p<0.05) in the survival of cultured 
RGC at concentrations of 1µM (255.5 ± 29.4 cells/well) and 10µm (263.5 ± 24.4 cells/well), 
but not at 0.1µM (148.3 ± 33.1 cells/well), compared to untreated controls (118.7 ± 18.7 
cells/well; Fig. 5.). 
By contrast, the percentage of surviving RGC bearing neurites in cultures of axotomised 
retinal neurons did not significantly change after treatment with 0.1µM (15.8 ± 1.4%), 1µM 
(10.0 ± 1.9%) or 10µM (10.9 ± 1.9%) when compared to untreated controls (17.3 ± 1.3%). 
The data suggest that VGF is a novel DPSC-derived neuroprotective, but not neuritogenic, 
factor for RGC at the optimal dose of 1µm.  
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Figure 5: The effects of VGF on RGC in retinal cultures. The total number of surviving RGC 
as well as the percentage of RGC bearing neurites either cultured alone, or with 0.1µM, 1µM 
and 10µM VGF (A). Asterisks indicate significant difference from other treatment groups at p 
< 0.05. RGC cultured either alone (Bi) or with 1µm VGF (Bii). All images are representative 
of the entire culture, nine separate culture wells/treatment with every three wells using 
different animals (scale bars: 100µm), cell nuclei were stained with DAPI. 
 
DISCUSSION 
We have previously shown that rat DPSC promoted neurotrophin-mediated neuroprotection 
and neuritogenesis/axogenesis of axotomised RGC, both in vitro and in vivo[17]. 
Interestingly, rat DPSC promoted significantly greater neuroprotection and axon 
regeneration than rat BMSC, which reportedly protect RGC from death in models of optic 
nerve crush and glaucoma[14,17]. We aimed to determine if the more potent neurotrophic 
properties were replicated by hDPSC, when compared to hBMSC and hAMSC and confirm 
that, like rat DPSC, hDPSC secreted multiple neuroprotective and axogenic NTF that 
protected RGC from death and promoted the growth of their neurites to a significantly 
112 
 
greater extent than either hAMSC or hBMSC, which both have distinct NTF profiles as 
determined by RT-PCR and ELISA. Thus, we conclude that hDPSC may constitute an 
effective paracrine-mediated cellular therapy for retinal, and potentially other CNS, 
injuries[17]. 
To determine the neuroprotective and neuritogenic effects of hDPSC-, hBMSC- and hAMSC- 
derived NTF, we cultured these human-derived stem cells with RGC. Similar to our previous 
results using rat stem cells[17], hDPSC and hBMSC stimulated RGC survival and 
neuritogenesis to levels greater than those seen in untreated control retinal cultures. 
Moreover, hDPSC were more neuroprotective and neuritogenic than hBMSC (although the 
former measure did not reach statistical significance), which corroborates our previous 
findings[17] as well as those of others showing greater functional restoration when hDPSC, 
as opposed to hBMSC, were transplanted into spinal cord lesion sites[32]. The 
neuroprotective and neuritogenic properties of hAMSC were significantly less than hDPSC 
and this was correlated with lower secreted levels of NGF, BDNF, NT-3, VEGF and GDNF 
observed by ELISA. 
We used Fc-NTFR fusion protein blockers to examine the mechanism of the hDPSC-, 
hBMSC- and hAMSC-mediated neuroprotection and neuritogenesis. The neuroprotective 
effect of hDPSC was significantly reduced after the addition of each individual Fc-NTFR, 
confirming the contribution of stem cell-derived NGF, BDNF, NT-3, GDNF, VEGF and 
PDGF-AA/AB/BB. Similar observations were seen with hBMSC, suggesting that the 
mechanisms for neuroprotection/neuritogenesis are similar and that the reduced 
neuroprotective effect of hBMSC compared to hDPSC is explained by the reduced 
neurotrophic profile. Moreover, hAMSC had a similar RGC protective/regenerative potency 
to hBMSC yet, owing to a lack of BDNF secretion, Fc-TrKB had no effect on hAMSC-
mediated RGC survival or neuritogenesis. Interestingly, Fc-PDGFBr reduced hDPSC-
/hBMSC-/hAMSC-mediated neuroprotection despite no PDGF-AB/BB being detected in 
conditioned media by ELISA. This might be explained by the previous observation that 
113 
 
PDGF-AB/BB was secreted at very low levels by hBMSC (40-fold < PDGF-AA)[15] and 
therefore expected to fall below the detectable range for the ELISA used. Thus, the efficacy 
of Fc-PDGFBr could be attributable either to the potency of low levels of PDGF-AB/BB or to 
PDGF-AB/BB secreted by glia present in the retinal cultures in response to hDPSC-/hBMSC-
/hAMSC-derived growth factor stimulation. 
The secretion of multiple NTF by hDPSC confirms previous findings showing NTF gene 
expression by hDPSC[19,20,32] as well as NTF secretion by rat-derived DPSC[17,33] and 
neurotrophins by hDPSC[21]. In concert with our findings using rat DPSC[17], hDPSC 
secreted significantly more NGF and BDNF than hBMSC. Interestingly, compared to 
previous data on rat DPSC, hDPSC secreted higher titres of NGF but lower titres of 
BDNF[17]. Our results confirmed those in the literature on the extensive NTF secretory 
profile of hBMSC including NGF, BDNF, NT-3 and GDNF[17,34-36], adding VEGF to the list 
of known secreted factors but failed to detect CNTF[32]. hAMSC secrete NGF, BDNF, NT-3, 
GDNF and VEGF[22,23]. However in the present study, we have not detected the secretion 
of BDNF and NT-3, possibly because the titre was below the detectable range of the ELISA 
or that none was secreted in this study. Our results also support the findings of recent 
studies by others showing that hBMSC secrete PDGF-AA[15] and extend this observation to 
show that hDPSC and hAMSC share this property. 
To further elucidate the relative neurotrophic activities of hDPSC, hBMSC and hAMSC, we 
conducted a RT-PCR array of 84 NTF/NTFR genes. The data showed that all three stem cell 
types have distinct NTF gene expression profiles. In particular, we found that hDPSC 
expressed prostaglandin E2 receptor (ptger2) at 6 and 10 fold higher than both hBMSC and 
hAMSC, respectively. Ptger2 stimulates the synthesis and release of neurotrophins from 
multiple cell types[37-39]. hDPSC also expressed over 100-fold lower interleukin-6 (il6) than 
hBMSC and hAMSC. The cytokine IL6 is neuroprotective after binding to the gp130 
receptor[40] and promotes axon regeneration after activating the JAK/STAT3 pathway[41]. 
As a pro-inflammatory cytokine it is likely there are other IL6-mediated effects not fully 
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realised in our in vitro paradigm. Finally, hBMSC express 6-fold higher fibroblast growth 
factor-9 (fgf9) than hDPSC, whereas hAMSC express over 700-fold higher fgf9 than hDPSC. 
FGF9, unlike other FGF isoforms, stimulates the survival of RGC by binding to FGF 
receptor-3[42], possibly highlighting a distinct mechanism for hAMSC-induced RGC 
neuroprotection. These data reinforce the notion that the stem cell origin is critical in 
determining their selection and application as cellular therapies for the treatment of particular 
neurological conditions. 
NTF analyses by ELISA corresponded well with the RT-PCR microarray data, a point 
particularly well illustrated by the correlative BDNF and GDNF protein and mRNA data. 
Interestingly NGF values for protein and mRNA were paradoxical; demonstrating lower 
levels of NGF gene expression in hDPSC compared to hBMSC/hAMSC, while the titres of 
NGF protein in the conditioned medium from hDPSC cultures was significantly higher than 
that in the medium from hBMSC/hAMSC. These findings underline some discrepancies 
between gene expression and NTF protein secretion, which may be explained by differences 
in either the timing of sampling (PCR reflecting a snap-shot event while protein levels are 
cumulative) or an abundance of pre-existing stores of NGF in hDPSC. 
The results presented here support the assertion that the RGC survival effects of the MSC 
are mediated in part by PDGF-AA[15]. Interestingly, inhibitors to the PDGFr did not 
significantly reduce RGC neuritogenesis, suggesting that MSC-derived PDGF is important 
for neuroprotection but not neuritogenesis in RGC. 
RGC neurite outgrowth appeared to be particularly dependent on hDPSC-, hBMSC- and 
hAMSC-derived NGF. Thus, considering the enhanced secretion of NGF by hDPSC, may 
explain why hDPSC are more neuritogenic than hBMSC and hAMSC. BDNF and NT-3 are 
also neuritogenic for RGC, since neurite outgrowth was suppressed by the cognate Fc-TrK 
inhibitors. Noteworthy, hAMSC promoted very little neuritogenesis, although the response 
was significantly reduced when all three TrK receptors were simultaneously blocked. 
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Finally, this study is the first to identify VGF as a novel factor expressed at higher levels (>4 
fold) in hDPSC than in hBMSC or hAMSC. VGF is a peptide present in the CNS and 
PNS[43] that protects motor neurons in animal models of amyotrophic lateral sclerosis[44] 
and increases the survival of cerebellar granule cells after serum deprivation[45]. We also 
showed that VGF was active in the retinal culture model at a concentration similar to that 
previously reported as active in other models of CNS injury[45]. In particular, VGF was 
significantly RGC neuroprotective, but not neuritogenic, suggesting that VGF may be 
involved in hDPSC-mediated RGC neuroprotection. Thus we propose that VGF may be a 
novel therapeutic NTF for RGC neuroprotection. 
In conclusion, our results show that hDPSC is a more potent stem cell type for paracrine-
mediated neuroprotection and regeneration of RGC than either hBMSC or hAMSC. The 
hDPSC-mediated neuroprotection and neuritogenesis is achieved through the paracrine 
effect of multiple secreted NTF, including PDGF (neuroprotection) and NGF (axon 
regeneration). Moreover, VGF is identified as a novel RGC neuroprotective factor expressed 
by hDPSC. hDPSC may represent an effective and advantageous cellular therapy for retinal 
nerve protection and repair. 
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Abstract 
Glaucoma is a leading cause of irreversible blindness involving loss of retinal ganglion cells 
(RGC). Mesenchymal stem cells (MSC) have shown promise as a paracrine-mediated 
therapy for compromised neurons. It is however unknown if dental pulp stem cells (DPSC) 
are effective as a cellular therapy in glaucoma and how their hypothesised influence 
compares to other more widely researched MSC sources. The present study aimed to 
compare the efficacy of adipose-derived stem cells, bone marrow-derived mesenchymal 
stem cells (BMSC) and DPSC in preventing the loss of RGC and visual function when 
transplanted into the vitreous of glaucomatous rodent eyes. Thirty five days after raised 
intraocular pressure (IOP) and intravitreal stem cell transplantation, Brn3a+ RGC numbers, 
retinal nerve fibre layer thickness (RNFL) and RGC function were evaluated by 
immunohistochemistry (IHC), optical coherence tomography (OCT) and electroretinography 
(ERG), respectively. Control glaucomatous eyes that were sham-treated with heat killed 
DPSC had a significant loss of RGC numbers, RNFL thickness and function compared with 
Intact eyes. BMSC and, to a greater extent, DPSC provided significant protection from RGC 
loss, RNFL thinning and preserved RGC function. The study supports the use of DPSC as a 
neuroprotective cellular therapy in retinal degenerative disease such as glaucoma. 
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1 Introduction 
Glaucoma is a common cause of irreversible blindness and is characterised by a 
degenerative loss of retinal ganglion cells (RGC) and their axons, leading to optic disc 
cupping and reduced visual acuity(1). Current treatments are designed to reduce intraocular 
pressure (IOP) to slow disease progression whereas neuroprotective treatments that directly 
target the injured RGC are still in their infancy. Neurotrophic factors (NTF), in particular 
neurotrophins, are neuronal survival factors that are retrogradely transported along a 
functionally connected axon to the soma maintaining the survival of connected neurons, but 
unconnected neurons die by apoptosis(2). Elevation of IOP significantly inhibits retrograde 
transport of NTF (3) and is one of the mechanisms involved in RGC death(4). NTF, 
especially when delivered in combinations, promote the survival of injured RGC in vitro (5, 
6). However their neuroprotective efficacy in vitro is not easily translatable to in vivo models 
as a constant delivery of multiple NTF is required for maintaining therapeutic effect.(7, 8)  
Mesenchymal stem cells (MSC) are multipotent self-replicating stromal cells are being 
evaluated as a cellular therapy for treating glaucoma based on their secretion of a wide array 
of NTF(9-12). MSC-derived NTF protect injured RGC, protecting them from death and 
ultimately preserving vision(13) and several clinical trials evaluating their neuroprotective 
efficacy are ongoing(14). MSC can be isolated from a variety of adult tissues such as bone 
marrow (BMSC) and adipose tissue (ADSC) but here we have focused on the use of MSC-
like cells from the dental pulp (DPSC). DPSC are multipotent cranial neural crest-derived 
stem cells(15, 16) that secrete significantly more NTF, including nerve growth factor (NGF), 
brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) than ADSC and 
BMSC(9, 10). We and others have demonstrated significant RGC neuroprotection by 
DPSC(9) and BMSC(17, 18) after traumatic optic neuropathy and shown in vitro that this 
neuroprotective effect is most likely due to NTF, including neurotrophins(9, 10) and platelet-
derived growth factor (PDGF)(12). These findings indicated that MSC, and in particular 
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DPSC, may be more effective as a treatment for neurodegenerative conditions such as 
glaucoma. 
We have demonstrated a significantly greater neuroprotective effect of DPSC compared to 
BMSC/ADSC in an in vitro model of RGC injury, with multiple secreted NTF being the 
mechanism behind the effect(10). We now hypothesise that DPSC may also be a candidate 
cellular therapy for protecting RGC from loss in glaucoma and determined to test this using 
an in vivo model. Accordingly, three widely researched stem cells for ocular repair(14), 
BMSC, ADSC and DPSC were transplanted into the vitreous body of rats in which ocular 
hypertension was induced using exogenously administered transforming growth factor-β1 
(TGF-β). Administration of TGF- β1(19) or TGF- β2(20, 21) are both accepted models that 
induce sustained elevations in IOP leading to significant RGC loss. In this study RGC 
survival was assessed using immunohistochemical quantification of Brn3+ RGC and retinal 
imaging using optical coherence tomography (OCT) of the retinal nerve fibre layer (RNFL) 
thickness.  Changes in retinal function were measured using electroretinography (ERG). 
2 Materials and Methods 
All reagents were purchased from Sigma (Poole, UK) unless otherwise specified. 
2.1 Human (h)DPSC/BMSC/ADSC cultures 
hDPSC were obtained from AllCell LLC (Berkeley, CA) and both hBMSC and hADSC from 
Lonza (Slough, UK), Each MSC batch represented pooled samples from 3 donors. The MSC 
were characterised by CD29+/CD44+/CD73+/CD90+/CD45- profile confirmed by the supplier) 
and demonstrated multi-differentiation (osteogenic, adipogenic and chondrogenic) capability. 
The stem cells were cultured  into T25/T75 flasks (Corning, Amsterdam, NL) in both a total 
volume of 5ml/15ml DMEM containing 1% penicillin/streptomycin and 10% foetal bovine 
serum (FBS; Hyclone Laboratories, Logan, UT) and at a density of 1x106 cells/2x106 cells, 
respectively. Cultures were maintained at 37°C in 5% CO2, the supplemented medium was 
changed every 3d and the cells were passaged when 80% confluent using 0.05% 
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trypsin/EDTA. One week before transplantation, cells were transfected with a gfp plasmid 
using lipofectamine 3000 (Life Technologies, Invitrogen, Paisley, UK) according to the 
manufacturer’s protocol. 
2.2 Experimental design 
Twelve rats (24 eyes) received bi-weekly (twice a week) bilateral intracameral (IC) injections 
of TGF-β0-35d (for 5 weeks) and were separated into 2 groups of 6. On 0d, Group 1 received 
an ivit transplantation of DPSC into one eye and dead DPSC (sham control) into the other 
eye (left and right eyes, respectively, in 3 rats, and vice versa in the remaining 3 rats). On 
0d, Group 2 received an ivit transplantation of BMSC into one eye and ADSC into the other 
eye (left and right eyes, respectively, in 3 rats, and vice versa in the remaining 3 rats). All 
rats in Group 1 and 2 received ERG and OCT recordings on 35d, before culling and tissue 
processing for immunohistochemistry. Animal numbers in each group were determined using 
a previously published power calculation(22, 23). A separate group of 6 rats received bi-
weekly unilateral IC injections of PBS0-35d and these rats are referred to as the Intact Group.  
2.3 Animals 
All animal procedures were performed in strict accordance to the UK Home Office Animals 
Scientific Procedures Act, 1986, and approved by the University of Birmingham Ethical 
Review Sub-Committee. Eighteen adult female Sprague Dawley rats weighing 150-200g 
(Charles River, Margate, UK) were housed in conditions of 21°C and 55% humidity under a 
12h light/dark cycle with a daytime luminance of 80 lux, given food/water ad libitum and were 
monitored by welfare staff. Gaseous anaesthesia was induced with 5% Isoflurane/1.5L per 
minute O2 (National Veterinary Supplies, Stoke, UK) and maintained at 3.5% during surgery 
and 2% during ERG recording. 
2.4 Surgery for IC injections to induce ocular hypertension and ivit transplantation of 
MSC 
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Following anaesthetic induction, IOP were recorded for all rats using an icare tonometer 
(Tonolab, Helsinki, Finland). Rats were then secured in a head-holding frame for IC 
injections of TGF-β1 (Peprotech, London, UK) through a single corneal incision, 2mm 
anterior to the limbus using a 15° blade (BD Ophthalmic System, Warwickshire, UK). Using 
the same incision site a glass micropipette, produced in-house from a glass capillary rod 
(Harvard Apparatus, Kent, UK) using a Flaming-Brown micropipette puller (Sutter 
Instruments, Novato, CA) was used to inject 3.5µl of 5µg/ml activated TGF-β1 IC into all 12 
rats. Contemporaneously, while the animals were still anaesthetised, a glass micropipette 
preloaded with 150,000 MSC suspended in 5µl of PBS, was used to inject living or dead 
cells (killed by heating for 30min at 80°C), into the vitreous of the eye (Fig. 1). After surgery, 
animals were placed in warm recovery cages and monitored for recovery of normal 
behaviour before being returned to their home cages. IOP recordings and IC injections of 
TGF-β were repeated bi-weekly0-35d throughout the study. A separate 6 rats (Intact Group) 
received bi-weekly0-35d IC injections of PBS alone. 
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Figure 1: Experimental design for the study. Time line of the in vivo experiment detailing 
when the stem cells were transplanted, glaucoma induction using bi-weekly injections of 
TGF-β and control animals using bi-weekly injections of PBS, ERG/OCT recording and day 
of animal culling. The group numbers and treatment regime for each eye are also given.  
 
2.5 Optical coherence tomography (OCT) of retinal nerve fibre layer 
OCT retinal nerve fibre layer analysis was performed at 35d on all rats while under inhalation 
anaesthesia using a Spectralis HRA3 confocal scanning laser ophthalmoscope (Heidelberg 
Engineering, Heidelberg, Germany). OCT images were taken of the retina around the optic 
nerve head and the in-built software was used to segment the images and quantify the 
RNFL thickness.  
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2.6 Electroretinography 
ERG (HMsERG; Ocuscience, Kansas City, MO) were recorded at 35d. Rats were dark 
adapted for 12 hours overnight and prepared for ERG recording under dim red light 
(>630nm). Scotopic flash ERG were recorded from -5.5 to +1  log units with respect to 
standard flash in half log-unit steps, using DTL fiber (Unimed Electrode Supplies, Farnham, 
UK) corneal electrodes with pressure-molded Aclar contact lenses and needle skin recording 
electrodes (Unimed Electrode Supplies).  
2.7 ERG analysis 
ERG traces were analysed using ERGVIEW (Ocuscience). Oscillatory potentials were 
removed by filtering waveforms above 20Hz from the trace before analysis. Traces at a light 
intensity of 1 and 3 mcd/s were chosen for analysis as they gave a clean, unambiguous 
positive scotopic threshold response (pSTR) with a mean latency of 100ms. The amplitude 
of the pSTR was measured from baseline. A representative, unfiltered trace is shown in 
Figure 5C. 
2.8 Tissue preparation 
Rats were given an intraperitoneal injection of 1ml sodium pentobarbital (National Veterinary 
Supplies) at 35d and perfused intracardially with 4% paraformaldehyde (PFA; TAAB, 
Reading, UK) in PBS while under terminal anaesthesia. Eyes were removed and immersion 
fixed in 4% PFA in PBS for 2h at 4°C before cryoprotection in 10%, 20% and 30% sucrose 
solution in PBS for 24h with storage at 4°C. Eyes were then embedded using optimal cutting 
temperature embedding medium (Thermo Shandon, Runcorn, UK) in peel-away mould 
containers (Agar Scientific, Essex, UK) by rapid freezing under crushed dry ice and stored at 
-80°C. After embedding, eyes were sectioned on a cryostat microtome (Bright, Huntingdon, 
UK) at -22°C at a thickness of 20 µm and mounted on positively charged glass slides 
(Superfrost Plus, Fisher Scientific, Pittsburgh, PA). Radial eye sections were left to dry on 
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slides overnight at 37°C before storage at -20°C. Standard eye sections containing the optic 
nerve head were used to account for variation in RGC density. 
2.9 Immunohistochemistry 
Mounted tissue sections were equilibrated to room temperature (RT), hydrated in PBS for 2 
X 5min, permeabilized in 0.1% triton x-100 in PBS for 20min at RT and washed for 2 X 5min 
in PBS before isolation with a hydrophobic PAP pen (Immedge pen; Vector Laboratories, 
Peterborough, UK). Non-specific protein binding sites in sections were blocked by incubation 
in blocking buffer (75µl; 0.5% bovine serum albumin (g/ml), 0.3% Tween-20, 15% normal 
goat/donkey serum (Vector Laboratories) in PBS) in a humidified chamber for 30min at RT 
and then sections were drained and incubated with either Brn3a primary antibody (1:200; 
Santa Cruz, CA, #SC-31984) or Stro1 primary antibody (1:100; R&D Systems, MN, 
#MAB1038) diluted in antibody diluting buffer (ADB; 0.5% bovine serum albumin, 0.3% 
Tween-20 in PBS) overnight at 4°C. The following day, slides were washed for 3 X 5min in 
PBS. Tissue sections were then incubated with Goat IgG Alexa 594 secondary antibody 
(1:400; Molecular Probes, Paisley, UK; #A-11058) diluted in ADB for 1h in a hydrated 
incubation chamber at RT. After 1h, slides were washed for 3 X 5min in PBS, mounted in 
Vectorshield mounting medium containing DAPI (Vector Laboratories) and stored at 4°C 
before microscopic analysis. 
2.10 Microscopy and analysis 
Fluorescently stained sections were analysed by an operator blinded to treatment groups, 
using a Zeiss Axioplan-2 fluorescent microscope (Carl Zeiss Ltd, Hertfordshire, UK). For 
immunohistochemistry, Brn3a+ RGC were counted in 20µm thick standard sections of the 
retina, along a 250µm linear region of the ganglion cell layer either side of the optic nerve, as 
described previously(22). Four sections per retina and 6 retinae from 6 different animals per 
treatment group were quantified. 
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2.11 Statistics 
All statistical tests were performed using SPSS 17.0 (IBMM SPSS, Inc., Chicago, IL) and 
data were presented as mean ± standard error of the mean (SEM). The Shapiro-Wilk test 
was used to ensure all data were normally distributed before parametric testing.  IOP data 
were measured using the generalised estimated equations (autoregressive correlation 
matrix). RGC survival and function data were tested for significance using 1-way ANOVA for 
>2 group comparisons ± SEM and Tukey post-hoc test. Statistical difference was considered 
significant at p values < 0.05. 
3 Results 
3.1 IC injections of TGF-β significantly raised IOP over 35d 
IC injections of TGF-β induced a significant increase in IOP by 7d (16.9 ± 2.3mmHg) 
compared to Intact (PBS injected) eyes (10.2 ± 0.7mmHg) which was maintained between 
14d (13.8 ± 0.7mmHg) and 35d (13.9 ± 0.9mmHg) compared to PBS (9.3 ± 0.2mmHg and 
11.4 ± 1.1mmHg, respectively; Fig. 2). No significance differences were seen at 3d and 10d. 
IOP measurements between the four separate MSC treatment groups IC injected with TGF-
β were not significantly different from each other at any time point (not shown). These data 
show that IC TGF-β injections raised IOP and that IOP was not affected by the IC injection of 
stem cells.  
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Figure 2: IOP in rats injected with either TGF-β or PBS. IOP measurements (mmHg) from 
rats IC injected with bi-weekly TGF-β (red line) or PBS (blue line) and ivit injected with stem 
cells (see Figure 1.) Note the acute peak rise in IOP at 7d and the chronically maintained 
elevation from 14d and beyond, all time points are significantly different from each other 
(p<0.05) unless otherwise stated (NS; Not Significant), as determined using the generalised 
estimated equations (autoregressive correlation matrix). The PBS data is from 6 eyes in 6 
rats, whereas the TGF-β data is consolidated from the 4 treatment groups (12 rats, 24 eyes). 
Note that no significant differences in IOP were seen between the TGF-β injected groups 
transplanted with different MSC (not shown). 
 
3.2 MSC protected eyes from elevated IOP-induced RNFL thinning  
The RNFL comprises axons belonging to the RGC and is lost concomitantly with the loss of 
the RGC cell body. TGF-β-induced elevations in IOP led to a significant RNFL thinning by 
35d (27.0 ± 1.8µm) compared to Intact controls (55.5 ± 0.6µm; Fig. 3). Intravitreal (ivit) 
transplantation of both BMSC and, to a greater degree, DPSC, preserved RNFL thickness 
(37.3 ± 0.6µm and 41.3 ± 1.3µm, respectively) compared to sham-treated (dead DPSC 
transplanted) eyes (27.0 ± 1.8µm). Ivit transplantation of ADSC did not affect IOP-induced 
loss of RNFL thickness (29 ± 0.8µm) compared to sham-treated eyes (27.0 ± 1.8µm). RNFL 
thickness in Intact eyes was significantly greater than the RNFL thickness in all 
treated/sham-treated eyes. 
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Figure 3: RNFL thickness after TGF-β-induced glaucoma in rats. OCT images of retina from 
an uninjured eye and a TGF-β-induced glaucomatous eye treated with ivit DPSC, BMSC, 
ADSC and dead DPSC (sham-treated) are shown (A) with red lines outlining the RNFL. The 
graph (B) depicts the RNFL thickness (µm) at 35d after glaucoma induction for the above 
treatment groups as well as for uninjured eyes. Asterisks indicate significant difference from 
all groups where as black lines indicate significant difference between particular groups 
(p<0.05), as determined using a 1-way ANOVA and Tukey post-hoc test. Measurements 
were taken from images of sections containing the optic nerve head, indicated by the green 
line (C). Images and data representative from 5 animals/eyes per treatment group (scale 
bar: 200µm). 
 
3.3 MSC protected eyes from elevated IOP-induced loss of RGC 
TGF-β-mediated elevations in IOP induced a significant 33% loss of RGC by 35d (49.0 ± 
1.6/mm of retina; sham-treated group) compared to Intact controls (73.2 ± 2.5/mm of retina; 
Fig. 4). Ivit transplantation of both BMSC and to a greater degree, DPSC, protected against 
this RGC loss and thus exhibited greater numbers of RGC (60.2 ± 1.3/mm of retina and 69.7 
± 1.9/mm of retina, respectively) compared with sham-treated eyes (49.0 ± 1.6/mm of 
retina). DPSC-induced RGC survival was significantly greater than that achieved by BMSC. 
Notably, RGC numbers in the DPSC treatment group was not different from RGC numbers 
in Intact healthy eyes. Interestingly, Ivit transplantation of ADSC did not affect RGC survival 
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(52.8 ± 1.9/mm of retina) compared with sham-treated eyes (49.0 ± 1.6µm/mm of retina). 
GFP+/Stro1+ MSC were detectable on the vitreal side of the inner limiting membrane in all 
animals at select regions throughout the eye (Fig. 4B). No evidence of migration into the 
retina was seen. 
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Figure 4: Brn3a+ RGC counts in standard radial eye sections. Immunohistochemically 
stained radially sectioned retina, stained for Brn3a (red), from Intact rats and rats IC injected 
with TGF-β for 35d and also ivit transplanted with DPSC, BMSC, ADSC and dead DPSC 
(sham-treated). All images are representative of the 8 images taken per retina from 6 
different animals (scale bar: 50µm). All images show tissues counterstained with the nuclear 
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marker DAPI (blue). In (B), GFP+ MSC stained for the MSC marker Stro1 identified in the 
vitreous, adhered to the inner limiting membrane. In (C), the mean number of Brn3a+ RGC in 
a 1mm region of retina either side of the optic nerve head is shown from each of the above 
groups. Black lines indicate significant difference between groups (p<0.01), as determined 
using a 1-way ANOVA and Tukey post-hoc test.  
 
3.4 MSC protected eyes from elevated IOP-induced loss of RGC function 
The pSTR represents the compound action potentials of RGC in response to the light 
dependant electrochemical signal originating from photoreceptors and thus its amplitude 
provides a read out of RGC function. TGF-β-mediated elevations in IOP induced a 
significant 85% loss of pSTR amplitude by 35d (21.2 ± 11.8µv) compared to Intact controls 
(140.8 ± 6.3µv; Fig. 5A). Ivit transplantation of both BMSC and to a greater degree, DPSC, 
protected against the RGC dysfunction associated with raised IOP and thus promoted 
greater preservation of pSTR (60.5 ± 18.3µv and 75.5 ± 17.4µv, respectively) compared to 
ADSC/sham-treated eyes (25.3 ± 7.8µv/21.2 ± 11.8µv, respectively), although this was only 
statistically different  for DPSC treated eyes. 
Recordings at a light intensity stimulus of 1000mcd/s as opposed to 3000mcd/s gave lower 
recordings of amplitude but the same relative differences (Fig. 5B) 
133 
 
 
Figure 5: pSTR response after TGF-β-induced glaucoma. The mean amplitude of the pSTR 
response from the eyes of Intact rats and rats IC injected with TGF-β for 35d and also ivit 
transplanted with DPSC, BMSC, ADSC and dead DPSC (sham-treated) after a receiving a 
flash intensity of 3000mcd/s (A) and 1000mcd/s (B). Asterisks indicate significant differences 
between all groups whereas black lines indicate significant difference between groups 
(p<0.05), as determined using a 1-way ANOVA and Tukey post-hoc test. In (C), a 
representative image is shown of the ERG traces with an observable pSTR response from 
Intact rats and from rats IC injected with TGF-β for 35d with ivit transplantation of DPSC or 
dead DPSC, 6 different animals per group. 
 
4 Discussion 
This study demonstrates for the first time that in a model of open angle glaucoma, DPSC 
promotes neuroprotection of injured RGC following ivit transplantation, preserving both their 
Brn3a+ cell body within the ganglion cell layer, axons within the RNFL and electrical function 
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as measured using ERG. Of note DPSC had the greatest therapeutic effect for RGC in this 
model of glaucoma whereas ADSC had the least. DPSC thus represent a potential effective 
cellular neuroprotective therapy for glaucoma patients. 
Open angle glaucoma is the most common form of glaucoma and is characterised by 
elevated IOP related to trabecular meshwork fibrosis that perturbs the aqueous outflow 
pathway, as opposed to physical obstruction of the pathway by the iris i.e. angle closure 
glaucoma. The TGF-β model of glaucoma used in this study is based on the observation that 
patients with open angle glaucoma have elevated levels of TGF-β in the aqueous 
humour(24). This, coupled with the observations that TGF-β is a potent pro-fibrotic cytokine 
and that fibrosis of the trabecular meshwork is a pathology that underpins the elevation in 
IOP in open angle glaucoma, makes this model a suitable representation of the human 
pathology. As seen in previous studies both from our laboratory and others(20, 21), TGF-β 
induced a reliable chronic rise in IOP and thus may be considered a suitable model to test 
neuroprotective cellular therapies relevant to glaucomatous RGC loss. 
Our findings are consistent with our previous study that showed  DPSC to be RGC 
neuroprotective in an optic nerve crush injury model(9). Optic nerve crush causes a rapid 
loss of RGC with approximately 90% dead by 3 weeks. DPSC promoted some 
neuroprotection of RGC when ivit transplanted, however, there was still approximately 60% 
RGC death after complete RGC axotomy. We postulated that the slow consistent release of 
NTF from MSC, would be better suited as a therapy for a chronic neurodegenerative 
condition, such as glaucoma where the retrogradle NTF supply is attenuated but still 
present, as opposed to an acute traumatic condition such as traumatic optic neuropathy, 
where the retrogradle NTF supply is completely ablated. 
The present study is the first to demonstrate both the potential of DPSC to treat 
glaucomatous eyes and also to show that their therapeutic neuroprotective effect is 
significantly greater than BMSC and ADSC transplantation. RGC survival increased from 
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67% after treatment with dead DPSC to 95% after treatment with living DPSC; notably a 
RGC count not significantly different from that in Intact animals. This result corroborates the 
neuroprotective effects observed after optic nerve crush(9), as well as in transplantation 
studies after spinal cord injury in the rat(25), both of which demonstrated that DPSC 
promoted greater neuronal survival than BMSC. Similar to the studies described above, we 
also found that the transplanted GFP+ MSC (stained for the MSC marker Stro1) survived 
within the vitreous space for the full length of the study with no evidence of migration into 
retinal tissue (Fig. 4B). 
Previous studies by Johnson et al, have explored the use of BMSC as a treatment for 
glaucoma(13, 26). In their earliest study, BMSC were ivit transplanted into a laser-induced 
ocular hypertensive glaucoma model. The model yielded a 40% loss of RGC axons 28d after 
induction of glaucoma, which was reduced to a 10% after ivit BMSC transplantation. In the 
present study, our model yielded a Brn3a+ RGC loss of 33% which was reduced to an 18% 
loss when eyes received ivit transplantation of BMSC. Possible explanations for why BMSC-
mediated neuroprotection was 30% in a previous study(13) and only 15% in the present 
study may be that: A), the present study used a different model of glaucoma which results in 
less RGC death and thus less potential for neuroprotection, and B), the present study 
counted Brn3a+ RGC whereas the Johnson et al, counted axons within the optic nerve, 
whose death precedes the loss of the RGC soma and will therefore yield greater disparities 
between treatment and control groups. A more recent study(27) has explored the use of 
BMSC as a treatment for open angle glaucoma and demonstrated a 17% increase in the 
survival of RGC, similar to the 15% neuroprotection observed in this study. However, the 
authors injected hyaluronic acid IC to elevate IOP instead of TGF-β (and thus this was a 
model of acute rather than chronic open angle glaucoma) and used animal-derived BMSC 
instead of human-derived as was used in the present study. 
As well as counting RGC somata we used OCT to measure the thickness of the RNFL which 
reflects RGC axon loss. The RNFL is comprised of axons of the RGC as they course over 
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the inner surface of the retina and towards the optic disc. Although axonal loss precedes 
RGC loss, the resolution of OCT is not as high as direct fluorescent microscopy making 
direct comparisons of the two measurements difficult. In addition, the RNFL contains 
astrocytes and retinal blood vessels and thus is not an absolute measure of RGC axon 
numbers. Despite this, we have previously shown that RNFL thickness is a reliable measure 
of moderate axonal loss but becomes inaccurate when the RNFL is substantially thinned (9). 
In the present study, RNFL thickness was reduced by 51% in the sham-treated 
glaucomatous eyes when compared to Intact controls. This is higher than the 33% loss in 
RGC reported, and can be explained by fact that in glaucoma, RGC axonal loss precedes 
RGC loss and will thus is expected to be higher(28, 29). Indeed, although the pattern of 
neuroprotection as inferred from the RNFL thickness (i.e. DPSC being the most efficacious 
followed by BMSC and ADSC showing no neuroprotection) is the same as determined from 
Brn3a+ RGC counts, there is more retinal cell “death” recorded by RNFL thickness 
measurements than Brn3a+ RGC counts of the same group for the above reason. 
The present study did not explore the mechanisms by which MSC elicit neuroprotection of 
RGC in glaucomatous eyes, or why DPSC have greater therapeutic efficacy than 
BMSC/ADSC. However, previous published studies by us and others provided strong 
evidence for paracrine-dependent effects. Perturbations in retrograde axonal transport of 
NTF have been implicated in the pathology of glaucoma(3, 4) and explains the success of 
NTF supplementation as a neuroprotective strategy(9-13). We have previously shown that 
DPSC, BMSC and ADSC secrete multiple NTF including NGF, BDNF, NT-3, glial cell line-
derived neurotrophic factor, vascular endothelial growth factor and PDGF(10), whereas a 
recent paper demonstrated that PDGF(12) was a significant contributor to the 
neuroprotective effects elicited by BMSC on injured RGC. Our results corroborate this, 
demonstrating a significant ablation of the neuroprotective effects of DPSC, BMSC and 
ADSC when NTF receptors are blocked in culture(9, 10). As after optic nerve crush, the 
present study found that DPSC were the most RGC neuroprotective stem cells out of the 
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tested MSC in our model of glaucoma which can be explained by their enhanced NTF profile 
in comparison to BMSC and ADSC(10). 
Our study did not find a neuroprotective effect of ADSC in this model of glaucoma. This is 
unsurprising given the reduced neurotrophic profile of ADSC in comparison to BMSC/DPSC, 
particularly since the neurotrophins BDNF and NT-3 showing no detectable expression(10). 
However, a recent previous study demonstrated a 19% RGC neuroprotective effect of ADSC 
after transplantation into the vitreous of an animal model of glaucoma(27). The disparity 
between the finding of this study and ours could be explained by: A), the use of a different 
model of glaucoma focusing on closed angle glaucoma rather than open angle glaucoma; 
B), study duration of only 4 weeks in comparison to our 5 weeks; and C), the study used 
ADSC derived from rats whereas the present study used ADSC derived from humans. 
Finally, we measured the amplitude of the pSTR after ERG recordings on rats, using this as 
a measure of RGC function. A previous study(30) induced ocular hypertension in rats by 
injecting hypertonic saline into the episcleral vein, 5 times per week for 5 weeks. They 
demonstrated a 50% decrease in pSTR amplitude which correlated with both raised IOP and 
optic nerve damage. Our study demonstrated an 80-85% decrease in RGC function in sham-
treated glaucomatous eyes compared to Intact eyes, a more profound effect than the 
previous study, which could be due to the difference in the animal model used. Interestingly, 
pSTR amplitude showed a similar pattern to the Brn3a survival and OCT RNFL thickness 
data, with DPSC and BMSC promoting the most significant RGC survival/functional 
preservation and ADSC/sham-treated eyes showing the least. There is a profound 
neuroprotective effect of DPSC on RGC, with RGC numbers no different from that of an 
Intact eye, but less functional preservation, with pSTR amplitude in the DPSC group 
significantly lower than in Intact eyes. This observation suggests that DPSC significantly 
protect RGC from death and dysfunction in glaucoma, however a portion of surviving RGC 
may still be dysfunctional or destined to die at a later time point, likely because of the 
underlying raised IOP. Indeed, a previous study(31) demonstrated a significant 50% 
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decrease in pSTR after only 75min of acute ocular hypertension (from 12mmHg to 60mmHg) 
suggesting, together with this study, that RGC function is more sensitive to raised IOP than 
is RGC survival. The data highlights the fact that IOP lowering drugs may still be a useful 
adjunct to a cellular neuroprotective therapy.  
Future work will focus on unravelling the precise mechanism for the paracrine-mediated 
neuroprotection of RGC and ensuring the safety of DPSC as a cellular therapy, for example, 
through the encapsulation of cells to prevent unwanted migration/proliferation(32), or the 
genetic integration of a “suicide gene” to ensure cells can be selectively removed with 
ganciclovir after transplantation(33).  
5 Conclusions 
We demonstrate here for the first time the potential of DPSC to act as a cellular therapy for 
glaucomatous visual loss by protecting RGC and their axons from death and preserving 
RGC function. In comparison to BMSC and ADSC, DPSC were the most efficacious and 
thus may potentially represent an “ideal” cell to be trialled as a neuroprotective treatment for 
glaucoma.  
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GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
142 
 
6.1 Main findings and future work 
Traumatic and degenerative eye disease leads to permanent blindness due both to an 
irreplaceable loss of retinal neurons and an irreparable degeneration of their axons. This 
research project attempted to protect injured RGC and regenerate their axons by exploiting 
DPSC as a neuroprotective/neuroregenerative cellular therapy, in comparison to BMSC and 
ADSC. The rat optic nerve crush model was used to model TON and transforming growth 
factor (TGF)-β-induced ocular hypertension was used to model glaucoma. As an adjunct to 
this hypothesis, the reliability of the preferred method of quantifying RGC (counting in radial 
sections) was tested and compared to the current gold standard of counting RGC in flat 
mounted whole retina.  
The first finding of this research is relevant to all ocular research and details how the 
quantification of Brn3a+ RGC for the determination of cell death and to evaluate the efficacy 
of neuroprotective treatments can be done just as reliably in radial sections of retina as the 
current gold standard for RGC quantitation, retinal wholemounts (Chapter 2; Mead et al., 
2014b). Since retinal wholemounts consume the whole tissue, whereas large numbers of 
radial retinal sections can be probed for multiple proteins, this allows for a greater degree of 
analysis while saving on animal costs. Moreover, the work validates the results generated 
from previous studies in the literature that have used radial sections to measure RGC death. 
The main focus of this research was to determine the most suitable stem cell therapy for 
traumatic and degenerative eye disease by testing the hypothesis that DPSC, a neural crest-
derived stem cell, would be the most efficacious stem cell phenotype. This hypothesis was 
supported partially by work done in the spinal cord (Sakai et al., 2012) that demonstrated a 
greater degree of functional improvement following DPSC transplantation when compared 
with BMSC. Using a model of TON, it was demonstrated that DPSC promoted a significant 
increase in the survival of RGC and regeneration of their axons compared to BMSC 
(Chapter 3; Mead et al., 2013). In an effort to determine the mechanism behind this effect, it 
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was decided to co-culture MSC with RGC and block specific NTF receptors. This experiment 
utilized human-derived MSC and also included ADSC, giving the research its clinical 
relevance and impact (Chapter 4; Mead et al., 2014a). The findings were that A), each of the 
three types of MSC (DPSC, BMSC and ADSC) had distinct neurotrophic secretory profiles; 
B), the neuroprotective and neuroregenerative efficacy of rat-derived DPSC was greater 
when compared to other rat-derived MSC (Mead et al., 2013) and was also greater than 
human-derived MSC and C), the mechanism of RGC neuroprotection, as well as 
axon/neurite regeneration, was attributable to multiple stem cell-derived NTF, including NGF, 
BDNF, NT-3 and PDGF, based on the use of permeable filters separating the DPSC from 
the RGC and the use of specific blockers of NTF receptors.  
Finally, the suitability of DPSC as a treatment for glaucoma was determined. The slow 
progressive release of NTF by DPSC suggested that DPSC are a more suitable treatment 
for slow degenerative diseases rather than for acute traumatic injuries, like TON. This 
hypothesis was confirmed with an almost complete neuroprotective effect of transplanted 
DPSC on RGC in a TGF-β-mediated rodent model of glaucoma (Hill et al., 2015), 
accompanied by an appreciable preservation in visual function (Chapter 5; Mead et al., 
2015; in submission). The fact that DPSC performed with greater efficacy than BMSC or 
ADSC makes this finding particularly pertinent to the on-going clinical trials utilizing BMSC 
as a therapy for ocular diseases, including glaucoma (Mead et al., 2015) and makes the 
findings particularly impactful. 
The next logical steps for this research are to: (1), test the efficacy of DPSC in a more widely 
used model of glaucoma, such as photocoagulation of the trabecular meshwork (Johnson et 
al., 2010) and (2), test MSC as a therapy for glaucoma in a different species, such as rabbit, 
to corroborate the conclusions. 
Since glaucoma is a long term condition, it is ideal that cells remain within the eye for 
extended periods, to avoid repeat injection. It has been demonstrated that MSC survive 
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within the vitreous for over 3-5 weeks (Johnson et al., 2010, Levkovitch-Verbin et al., 2010, 
Mead et al., 2013, Haddad-Mashadrizeh et al., 2013) but a more long term study would be 
necessary to accurately predict their longevity in humans. Equally, the safety of stem cell 
transplantation for the recipient is under researched although stem cell tumorigenicity and 
uncontrolled proliferation is unlikely based on the numerous studies in rodents (Johnson et 
al., 2010, Singh et al., 2012, Mendel et al., 2013, Mesentier-Louro et al., 2014, Tzameret et 
al., 2014, Tan et al., 2015) and the on-going clinical trials (Mead et al., 2015) will further 
corroborate this. Removal of the stem cells from the eye could be achieved by transfecting 
the stem cells with a suicide gene to render them susceptible to selective loss by ganciclovir 
acts as a failsafe (Zhang et al., 2011), whereas encapsulating the cells in a permeable 
membrane prevents unbridled proliferation and migration (Sieving et al., 2006) and allows 
physical removal at the end of the treatment.  
Finally, this project concentrated on comparisons between DPSC, BMSC and ADSC, 
however, other stem cells are good candidates for the treatment of traumatic and 
degenerative eye disease. For example, umbilical cord-derived MSC are RGC protective 
and promote regeneration of their axons after optic nerve transection (Zwart et al., 2009). 
Equally, NSC have paracrine potential in models of SCI (Lu et al., 2003) and their use in the 
eye for RGC survival would be worth future study. 
6.2 Conclusions 
The findings described in this thesis confirm the reliability and accuracy of counting RGC in 
radial sections of retina as a method for quantifying RGC survival and neuroprotection in 
rats. Using this method and others, a neuroprotective and axogenic effect of DPSC on 
injured RGC in a model TON was demonstrated. The observation that DPSC were 
significantly more neuroprotective/axogenic than BMSC was likely due to the enhanced NTF 
secretion by DPSC. Finally it was demonstrated that DPSC, in comparison to both BMSC 
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and ADSC, significantly protected RGC from death and preserved visual function in a rat 
model of glaucoma. 
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